



US 20040191903A1

(19) **United States**

(12) **Patent Application Publication** (10) **Pub. No.: US 2004/0191903 A1**
Crowe et al. (43) **Pub. Date: Sep. 30, 2004**

(54) **METHOD AND THERAPEUTIC PLATELETS**

(60) Provisional application No. 60/430,040, filed on Nov. 29, 2002.

(76) Inventors: **John H. Crowe**, Davis, CA (US); **Fern Tablin**, Davis, CA (US); **Willem Wolkers**, Davis, CA (US); **Naomi Walker**, Davis, CA (US); **Sheri Looper**, Elk Grove, CA (US); **Nelly M. Tsvetkova**, Davis, CA (US); **Zsolt Torok**, Davis, CA (US)

Publication Classification

(51) **Int. Cl.⁷** **C12N 5/00; C12N 5/02**
(52) **U.S. Cl.** **435/374**

Correspondence Address:
CARPENTER & KULAS, LLP
1900 EMBARCADERO ROAD
SUITE 109
PALO ALTO, CA 94303 (US)

(57) **ABSTRACT**

(21) Appl. No.: **10/724,545**

A method for loading a preservative into a biological sample comprising providing a preservative solution having a preservative, water and protein, and loading a biological sample with the preservative solution to produce a preservative-loaded biological sample having the preservative solution generally including higher glass transition temperatures than glass transition temperatures for a preservative solution having the preservative, water and no protein. A process for processing biological samples comprising suspending biological samples in a preservative solution at a concentration greater than about 10⁸ platelets per ml. of preservative solution to produce preservative-loaded biological samples, freeze-drying the preservative-loaded biological samples, and recovering at least 75% of the freeze-dried biological samples. A biological sample composition comprising a biological sample loaded with a preservative solution having a preservative, water, and protein, and generally further having higher glass transition temperatures than glass transition temperatures for the biological sample loaded with the preservative, water, but no protein.

(22) Filed: **Nov. 28, 2003**

Related U.S. Application Data

(63) Continuation-in-part of application No. 10/635,353, filed on Aug. 6, 2003.
Continuation-in-part of application No. 10/052,162, filed on Jan. 16, 2002, now Pat. No. 6,770,478, which is a continuation-in-part of application No. 09/927,760, filed on Aug. 9, 2001, which is a continuation-in-part of application No. 09/828,627, filed on Apr. 5, 2001, now Pat. No. 6,723,497, which is a continuation of application No. 09/501,773, filed on Feb. 10, 2000, now abandoned.




FIG. 1




FIG. 2




FIG. 3




FIG. 4




FIG. 5




FIG. 6




FIG. 7



FIG. 8A
(PRIOR ART)



FIG. 8B





FIG. 9






Fig 17




Figure 18




Figure 19




Figure 20




Figure 21






Figure 22




0 hrs (control)

Figure 23




1 hr

Figure 24



3.5 hrs

Figure 25



5 hrs

Figure 26

State diagram of trehalose and trehalose/albumin (1/1, w/w)




Fig. 27

Total dry mass in freeze-drying buffer increases survival




Fig. 28




Fig 29




Fig 30




Fig 31




Fig. 32.




Fig 33




Fig 34




Fig 35




Fig 36




Fig 37




Fig 38




Fig 39

Survival of rehydrated (n = 5) and control (n = 8) CMFDA labeled platelets in circulation of NIH/SW mice




Fig 40

METHOD AND THERAPEUTIC PLATELETS

RELATED PATENT APPLICATIONS

[0001] This patent application is a continuation-in-part patent application of co-pending U.S. Provisional Application having Serial No. 60/430,040, filed Nov. 29, 2002, fully incorporated herein by reference thereto as if repeated verbatim immediately hereinafter. Benefit of the earlier filing date of Nov. 29, 2002 is claimed, particularly with respect to all common subject matter.

[0002] This patent application is also a continuation-in-part application of co-pending patent application having Ser. No. 10/635,353, filed Oct. 6, 2003, fully incorporated herein by reference thereto as if repeated verbatim immediately hereinafter.

[0003] This patent application is also a continuation-in-part patent application of co-pending patent application Ser. No. 10/052,162, filed Jan. 16, 2002. Patent application Ser. No. 10/052,162 is a continuation-in-part patent application of co-pending patent application Ser. No. 09/927,760, filed Aug. 9, 2001. Patent application Ser. No. 09/927,760 is a continuation-in-part patent application of co-pending patent application Ser. No. 09/828,627, filed Apr. 5, 2001. Patent application Ser. No. 09/828,627 is a continuation patent application of patent application Ser. No. 09/501,773, filed Feb. 10, 2000. The foregoing mentioned patent applications are fully incorporated herein by reference thereto as if repeated verbatim immediately hereinafter. Benefit of all earlier filing dates is claimed with respect to all common subject matter.

STATEMENT REGARDING FEDERAL SPONSORED RESEARCH AND DEVELOPMENT

[0004] Embodiments of this invention were made with Government support under Grant No. N66001-03-1-8927, awarded by the Department of Defense Advanced Research Projects Agency (DARPA). Further embodiments of this invention were made with Government support under Grant Nos. HL57810 and HL61204, awarded by the National Institutes of Health. The Government has certain rights to embodiments of this invention.

FIELD OF THE INVENTION

[0005] Embodiments of the present invention generally broadly relate to biological samples, such as mammalian cells, platelets, and the like. More specifically, embodiments of the present invention generally provide for the preservation and survival of biological samples.

[0006] Embodiments of the present invention also generally broadly relate to the therapeutic uses of biological samples; more particularly to manipulations or modifications of biological samples, such as loading biological samples with solutes (e.g., carbohydrates, such as trehalose) and preparing dried compositions that can be re-hydrated at the time of application. When biological samples for various embodiments of the present invention are re-hydrated, they are immediately restored to viability.

[0007] The compositions and methods for embodiments of the present invention are useful in many applications, such

as in medicine, pharmaceuticals, biotechnology, and agriculture, and including transfusion therapy, as hemostasis aids and for drug delivery.

BACKGROUND OF THE INVENTION

[0008] A biological sample includes cells and blood platelets. A cell is typically broadly regarded in the art as a small, typically microscopic, mass of protoplasm bounded externally by a semi-permeable membrane, usually including one or more nuclei and various other organelles with their products. A cell is capable either alone or interacting with other cells of performing all the fundamental function(s) of life, and forming the smallest structural unit of living matter capable of functioning independently.

[0009] Cells may be transported and transplanted; however, this requires preservation which includes drying (e.g., vacuum drying, air drying, etc.), freezing and subsequent reconstitution (e.g., thawing, re-hydration, etc.) after transportation. Unfortunately, a very low percentage of cells retain their functionality after undergoing freezing and thawing. While some protectants, such as the cryoprotectant such as dimethylsulfoxide, tend to lessen the damage to cells, they still do not prevent some loss of cell functionality.

[0010] Blood platelets are typically generally oval to spherical in shape and have a diameter of 2-4 μm . Today platelet rich plasma concentrates are stored in blood bags at 22° C.; however, the shelf life under these conditions is limited to five days. The rapid loss of platelet function during storage and risk of bacterial contamination complicates distribution and availability of platelet concentrates. Platelets tend to become activated at low temperatures. When activated they are substantially useless for an application such as transfusion therapy. Therefore, the development of preservation methods that will increase platelet lifespan is desirable.

[0011] Trehalose has been found to be suitable in the preservation of cells and platelets. Trehalose is a disaccharide found at high concentrations in a wide variety of organisms that are capable of surviving almost complete dehydration. Trehalose has been shown to stabilize membranes, proteins, and certain cells and platelets during drying (e.g., freeze-drying) *in vitro*.

[0012] Spargo et al., U.S. Pat. No. 5,736,313, issued Apr. 7, 1998, have described a method in which platelets are loaded overnight with an agent, preferably glucose, and subsequently lyophilized. The platelets are preincubated in a buffer and then are loaded with carbohydrate, preferably glucose, having a concentration in the range of about 100 mM to about 1.5 M. The incubation is taught to be conducted at about 10° C. to about 37° C., most preferably about 25° C.

[0013] U.S. Pat. No. 5,827,741, Beattie et al., issued Oct. 27, 1998, discloses cryoprotectants for human cells and platelets, such as dimethylsulfoxide and trehalose. The cells or platelets may be suspended, for example, in a solution containing a cryoprotectant at a temperature of about 22° C. and then cooled to below 15° C. This incorporates some cryoprotectant into the cells or platelets, but not enough to prevent hemolysis of a large percentage of the cells or platelets.

[0014] Accordingly, a need exists for the effective and efficient preservation of biological samples, such as platelets

and cells, and the like. More specifically, and accordingly further, a need also exists for the effective and efficient preservation of platelets and cells (e.g., erythrocytic cells, eukaryotic cells, or any other cells, and the like), such that the preserved platelets and cells respectively maintain their biological properties and may readily become viable after storage.

SUMMARY OF EMBODIMENTS OF THE INVENTION

[0015] In one aspect of the present invention, a dehydrated composition is provided comprising dried biological sample(s) (e.g., freeze-dried platelets and cells) that are effectively loaded with a solute (e.g., trehalose) to preserve biological properties during drying, freezing and rehydration. Biological samples comprising platelets are rehydratable so as to have a normal response to at least one agonist, such as thrombin. For example, substantially all freeze-dried platelets for various embodiments of the invention when rehydrated and mixed with thrombin (1 U/ml) form a clot within three minutes at 37° C. The dehydrated biological sample(s) may include one or more other agents, such as antibiotics, antifungals, growth factors, or the like, depending upon the desired therapeutic application.

[0016] Embodiments of the present invention provide improved compositions and improved methods for stabilizing blood platelets (e.g., human blood platelets) following freeze drying, particularly with respect to one or more of the following: (i) the freeze-drying buffer; (ii) scaling-up to clinically relevant cell concentrations and consequential survival of cells; (iii) long term stability of freeze-dried cells; (iv) prehydration over water vapor for optimal survival; and (v) response to agonists.

[0017] Embodiments of the present invention also provide improved compositions and improved methods with respect to loading blood platelets with trehalose and freeze drying them. A model is proved to examine the circulation of freeze-dried allogeneic platelets in mice. Mouse platelet circulation time may be determined by the infusion of fluorescently labeled control (fresh) or freeze-dried platelets. The circulation time for freeze-dried platelets is approximately 30% to 70% (e.g., approximately 50%) of fresh platelets, as determined by flow cytometric analysis.

[0018] Embodiments of the present invention provide a process for loading a biological sample comprising loading a biological sample with a solute (e.g., trehalose) by fluid phase endocytosis to produce an internally loaded biological sample. The loading of a biological sample by fluid phase endocytosis comprises fusing within the biological sample a first matter (e.g., a vesicle) with a second matter (a lysosome) to produce a fused matter. The fused matter preferably comprises the solute. The loading of a biological sample by fluid phase endocytosis additionally comprises transferring the solute from the fused matter into a cytoplasm within the biological sample. The fused matter may comprise a lower pH than a pH of the first matter. The fused matter preferably comprises a pH of less than about 6.5. The biological sample may include a biological sample selected from a group of biological samples comprising a platelet and a cell.

[0019] Embodiments of the present invention also provide a process for preparing a dehydrated biological sample comprising providing a biological sample selected from a

mammalian species, loading the biological sample with a solute by fluid phase endocytosis to produce a loaded biological sample, and drying the loaded biological sample to produce a dehydrated biological sample. The loading of the biological sample with a solute comprises loading of the biological sample with an oligosaccharide from an oligosaccharide solution, and preferably includes increasing a loading efficiency of the oligosaccharide into the biological sample by maintaining a concentration of the oligosaccharide in the oligosaccharide solution at less than a certain concentration (e.g., about 50 mM). The loading with an oligosaccharide includes loading with a loading efficiency ranging from about 45% to about 50% for the oligosaccharide solution having an oligosaccharide concentration ranging from about 20 mM to about 30 mM. The loading is preferably without a fixative. The process for preparing a dehydrated biological sample additionally comprises lyophilizing the biological sample, and prehydrating the lyophilized biological sample, preferably by exposing the lyophilized biological sample to moisture saturated air. When the biological sample comprises a platelet, and the process additionally comprises prehydrating the lyophilized platelet until the water content of the lyophilized platelet ranges from about 35% by weight to about 50% by weight.

[0020] Embodiments of the present invention provide a method for loading a preservative into a biological sample comprising providing a preservative solution having a preservative, water and protein, and loading a biological sample with the preservative solution to produce a preservative-loaded biological sample wherein the preservative solution generally has higher glass transition temperatures than glass transition temperatures for a preservative solution having the preservative, water and no protein. The preservative solution in the preservative-loaded biological sample comprises a gradient of the glass transition temperature (degrees C) to a water content (grams of water per gram of dry weight of preservative and protein) ranging from about 50 to about 900 at a water content of less than about 0.40 grams of water per gram of dry weight of preservative and protein. The glass transition temperature of the preservative solution in the preservative-loaded biological sample increases at a water content of less than about 0.40 grams of water per gram dry weight of preservative and protein. The preservative solution in the preservative-loaded biological sample comprises a greater rate of glass transition temperature per water content (weight of water per dry weight of preservative and protein) increase at a water content of less than about 0.25 grams of water per gram dry weight of preservative and protein than at a water content greater than about 0.25 grams of water per gram dry weight of preservative and protein.

[0021] Embodiments of the present invention provide a biological composition comprising a biological sample having a preservative solution including a preservative, water, and protein, and generally having higher glass transition temperatures than glass transition temperatures for the biological sample loaded with the preservative, water, but no protein. The biological sample comprises a gradient of the glass transition temperature (degrees C) to a water content (grams of water per gram of dry weight biological sample) ranging from about 50 to about 900 at a water content of less than about 0.40 grams of water per gram of dry weight biological sample.

[0022] Embodiments a process for processing biological samples comprising of the present invention provide providing a preservative solution having a preservative, water, and protein, suspending biological samples in the preservative solution at a concentration greater than about 108 biological samples per ml. of preservative solution to produce preservative-loaded biological samples, freeze-drying the preservative-loaded biological samples, and recovering at least 75% of the freeze-dried biological samples. The preservative solution comprises from about 60 mM to about 240 mM of the preservative and from about 2% by weight to about 8% by weight of the protein. The process additionally comprises storing, prior to recovering, the freeze-dried biological samples for more than 600 days.

[0023] Embodiments of the present invention provide a process for preserving protein structure in a biological sample comprising providing a preservative solution having a preservative, water and protein, loading a biological sample with the preservative solution to produce a preservative-loaded biological sample, dehydrating the preservative-loaded biological sample while maintaining a residual water content in the biological sample equal to or less than about 0.30 gram of residual water per gram of dry weight biological sample to preserve protein structure of the biological sample upon rehydrating after storage, storing the dehydrated preservative-loaded biological sample, and rehydrating the stored dehydrated preservative-loaded biological sample with water vapor to preserve protein structure of the biological sample. The rehydrating of the stored dehydrated preservative-loaded biological sample with water vapor comprises increasing the water content of the preservative-loaded biological sample until the preservative-loaded biological sample has a water content equal to or less than about 0.30 grams of water per gram of dry weight biological sample. The process may additionally comprises directly hydrating with bulk water the rehydrated preservative-loaded biological sample.

[0024] Embodiments of the present invention provide a dehydrated composition for mammalian therapy comprising freeze-dried biological samples comprising a preservative solution for preserving biological properties during freeze-drying and rehydration, wherein the preservative solution includes water, protein, and a preservative, and the biological samples are rehydratable so as to have a normal response to at least one agonist. The normal response to at least one agonists includes a response to thrombin in a physiological concentration commencing at thrombin concentrations ranging from about 0.1 U/ml to about 1.0 U/ml, and wherein between thrombin concentrations ranging from about 0.2 U/ml to about 0.70 U/ml, percent(%) aggregation of the rehydrated biological samples ranges from about 20% to about 80%. The normal response to at least one agonists includes a response to ristocetin in a physiological concentration commencing at ristocetin concentrations ranging from about 1.0 mg/ml to about 10.0 mg/ml.

[0025] Embodiments of the present invention further provide a process for loading a preservative into a biological sample comprising providing a preservative solution having a preservative, water and protein, disposing a biological sample in the preservative solution for loading the preservative from the preservative solution into the biological sample to produce a preservative-loaded biological sample wherein the preservative solution generally has higher glass

transition temperatures than glass transition temperatures for a preservative solution having the preservative, water and no protein, and preventing a decrease in a loading efficiency gradient in the loading of the preservative into the biological sample. The preservative comprises an oligosaccharide and the preventing a decrease in a loading efficiency gradient in the loading of the oligosaccharide into the biological sample comprises maintaining a concentration of the oligosaccharide in the oligosaccharide solution below about 50 mM. The loading comprises loading by fluid phase endocytosis. The preventing a decrease in a loading efficiency gradient in the loading of the oligosaccharide into the biological sample comprises maintaining a positive gradient of loading efficiency to concentration of the oligosaccharide in the oligosaccharide solution.

[0026] Embodiments of the present invention further also provide a process for loading a preservative into a biological sample comprising providing a preservative solution having a preservative, water and protein, disposing a biological sample in the preservative solution for loading the preservative from the preservative solution into the biological sample to produce a preservative-loaded biological sample wherein the preservative solution generally has higher glass transition temperatures than glass transition temperatures for a preservative solution having the preservative, water and no protein, and preventing a decrease in a loading gradient in the loading of the oligosaccharide into the biological sample. The preventing a decrease in a loading gradient in the loading of the oligosaccharide into the biological sample comprises maintaining a concentration of the oligosaccharide in the oligosaccharide solution below about 50 mM.

[0027] In another aspect of embodiments of the present invention, a hemostasis aid is provided where the above described freeze-dried platelets are carried on or by a biocompatible surface. A further component of the hemostasis aid may be a therapeutic agent, such as an antibiotic, an antifungal, or a growth factor. The biocompatible surface may be a bandage or a thrombic surface, such as freeze-dried collagen. Such a hemostasis aid can be rehydrated just before the time of application, such as by hydrating the surface on or by which the platelets are carried, or, in case of an emergency, the dry hemostasis treatment aid could be applied directly to the wound or burn and hydrated in situ.

[0028] Methods of making and using various embodiments of the present invention are also described. One such method is a process of preparing a dehydrated composition comprising providing a source of platelets, effectively loading the platelets with trehalose to preserve biological properties, cooling the trehalose loaded platelets to below their freezing point, and lyophilizing the cooled platelets. The trehalose loading includes incubating the platelets at a temperature from greater than about 25° C. to less than about 40° C. with a trehalose solution having up to about 50 mm trehalose therein. The process of using such a dehydrated composition further may comprise rehydrating the platelets. The rehydration preferably includes a prehydration step wherein the freeze-dried platelets are exposed to warm, saturated air for a time sufficient to bring the water content of the freeze-dried platelets to between about 20 weight percent to about 35 weight percent.

[0029] In yet another aspect of embodiments of the present invention, a drug delivery composition is provided compris-

ing platelets having a homogeneously distributed concentration of a therapeutic agent therein. The drug delivery composition is particularly useful for targeting the encapsulated drug to platelet-mediated sites.

[0030] Practice of embodiments of the present invention permits the manipulation or modification of platelets while maintaining, or preserving, biological properties, such as a response to thrombin. Further, use of the method to preserve platelets can be practiced on a large, commercially feasible scale, and avoids platelet activation. Embodiments of the freeze-dried platelets, and hemostasis aids including the freeze-dried platelets, are substantially shelf stable at ambient temperatures when packaged in moisture barrier materials.

[0031] These provisions together with the various ancillary provisions and features which will become apparent to those skilled in the art as the following description proceeds, are attained by the processes and biological samples (e.g., platelets, eukaryotic cells, and erythrocytic cells) of the present invention, preferred embodiments thereof being shown with reference to the accompanying drawings, by way of example only, wherein:

BRIEF DESCRIPTION OF THE DRAWINGS

[0032] FIG. 1 graphically illustrates the loading efficiency of trehalose plotted versus incubation temperature of human platelets.

[0033] FIG. 2 graphically illustrates the loading efficiency (cytosolic concentration divided by the extracellular concentration, the sum multiplied by 100) following incubation as a function of incubation time.

[0034] FIG. 3 graphically illustrates the internal trehalose concentration of human platelets versus external trehalose concentration as a function of temperature at a constant incubation or loading time.

[0035] FIG. 4 graphically illustrates the loading efficiency of trehalose into human platelets as a function of external trehalose concentration.

[0036] FIG. 5 graphically illustrates the recovery of platelet embodiments after lyophilization and direct rehydration with various concentrations of trehalose in the drying buffer, and in a combination of 30 mM trehalose and one percent HSA in the drying buffer.

[0037] FIG. 6 graphically illustrates the uptake of FITC dextran versus the external concentration compared with that of the marker, LYCH (with an incubation time of four hours).

[0038] FIG. 7 graphically illustrates the effect of prehydration on optical density of platelets.

[0039] FIG. 8 illustrates the response of 500 μ l platelets solution (with a platelet concentration of 0.5×10^8 cells/ml) that was transferred to aggregation vials, thrombin added (1 U/ml) to each sample, and the samples stirred for three minutes at 37° C., where panel (A) are the prior art platelets and panel (B) are the inventive platelets.

[0040] FIG. 9 graphically illustrates clot formation where the absorbance falls sharply upon addition of thrombin (1

U/ml) and the platelet concentration drops from 250×10^6 platelets/ml to below 2×10^6 platelets/ml after three minutes for the inventive platelets.

[0041] FIG. 10 is an exemplary diagram of a biological sample having a plasma membrane with an internal protein coating and encapsulating a cytoplasm having lysosomes and a nucleus.

[0042] FIG. 11 is an elevational view of the plasma membrane in contact with a solute solution having a solute which is to be loaded into the biological sample.

[0043] FIG. 12 is an elevational view of the plasma membrane in the process of being loaded with a solute.

[0044] FIG. 13 is an elevational view of a vesicle containing a solute and connected to the plasma membrane.

[0045] FIG. 14 is a diagram of the cytoplasm having a lysosome and a vesicle containing a solute and which "budded off" or released from the plasma membrane.

[0046] FIG. 15 is a diagram of a lysosome fused with a vesicle to produce fused matter or material containing a solute.

[0047] FIG. 16 is a diagram of the fused matter or material containing a solute which is in the process of passing in direction of the arrow from the fused matter or material into the cytoplasm of the biological sample to effectively load the biological sample with the solute.

[0048] FIG. 17 is an enlarged chemical structural, chain formula diagram of trehalose, a non-reducing disaccharide of glucose, with an arrow pointing to a glycosidic bond.

[0049] FIG. 18 is an enlarged chemical structural, chain formula diagram of sucrose, a non-reducing disaccharide of glucose and fructose, with an arrow pointing to a glycosidic bond which is much more susceptible to hydrolysis than the glycosidic bond in trehalose.

[0050] FIG. 19 is a graph of pH vs. % intact (i.e., % non-degraded) for trehalose and sucrose.

[0051] FIG. 20 is a graph of % leakage of a fluorescent dye, carboxyfluorescein (CF), from phospholipid vesicles as a function of pH and time.

[0052] FIG. 21 is a graph of rates of leakage (% leakage/10 minutes) as a function of pH.

[0053] FIG. 22 is a graph of projected time to achieve 100% leakage, based on FIGS. 20 and 21, as a function of pH.

[0054] FIG. 23 is a picture of control cells at zero (0) incubations time, showing no leakage of Lucifer yellow dye into the cytoplasm of the control cell.

[0055] FIG. 24 is a picture of cells after 1 hour incubation time, showing Lucifer yellow dye in punctate structures (i.e., endocytotic vesicles) with some leakage of Lucifer yellow dye into the cytoplasm.

[0056] FIG. 25 is a picture of cells after 3.5 hours incubation time, showing Lucifer yellow dye in punctuated structures (i.e., endocytotic vesicles) with more leakage of Lucifer yellow dye into the cytoplasm than the leakage represented in the picture of FIG. 24.

[0057] FIG. 26 is a picture of cells after 5.0 hours incubation time, showing a uniform stain of Lucifer yellow dye which suggests that Lucifer yellow dye has leaked into the cytoplasm.

[0058] FIG. 27 is a state diagram of glass transition temperature vs. water content for trehalose-albumin and trehalose alone, illustrating that the use of albumin elevates the glass transition temperature.

[0059] FIG. 28 is a recovery (survival) vs. cell count diagram of effects for increasing trehalose and albumin concentrations of survival of freeze-drying by human platelets.

[0060] FIG. 29 is a relative cell count vs. time diagram for stability of platelets in the freeze-dried state, suggesting that the shelf life for at least partially active platelets will be at least two years.

[0061] FIG. 30 is a relative percentage vs. volume diagram of the effects of prehydration (followed by rehydration) and direct rehydration on platelet volume.

[0062] FIG. 31 is a diagram illustrating the effects of prehydration over water vapor on phase behavior of freeze-dried platelets.

[0063] FIG. 32 is a diagram illustrating the effects of prehydration over water vapor on cooperativity of the phase transition of freeze-dried platelets.

[0064] FIG. 33 is a diagram illustrating the effects of direct rehydration on protein secondary structure in freeze-dried platelets, particularly reflecting that direct rehydration significantly alters protein secondary structure relative to control levels.

[0065] FIG. 34 is a diagram illustrating the effects of prehydration on protein secondary structure in freeze-dried platelets, particularly reflecting that prehydration returns protein secondary structure to control levels before rehydration in bulk water.

[0066] FIG. 35 is a transmittance vs. time diagram illustrating aggregometry traces for fresh control and freeze-dried (and rehydrated) platelets.

[0067] FIG. 36 is an aggregation vs. thrombin diagram, illustrating a thrombin dose-response curve for control and rehydrated platelets.

[0068] FIG. 37 is an aggregation vs. ristocetin diagram, illustrating a ristocetin dose-response curve for control and rehydrated platelets.

[0069] FIG. 38 is a percent aggregated vs. collagen diagram, illustrating a collagen dose response curve for fresh platelets.

[0070] FIG. 39 is a percent aggregated vs. collagen diagram, illustrating a collagen dose response curve for freeze-dried rehydrated platelets.

[0071] FIG. 40 is a percent circulation vs. survival of rehydrated (n=5) and control (n=8) carboxy-methyl fluorescein diacetate (CMFDA) labeled platelets circulating in mice.

DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS OF THE INVENTION

[0072] Embodiments of the present invention broadly include biological samples, preferably mammalian biological

samples. Embodiments of the present invention further broadly include methods for preserving biological samples, as well as biological samples that have been manipulated (e.g., by drying to produce dehydrated biological samples) or modified (e.g., loaded with a chemical or drug) in accordance with methods of the present invention. Embodiments of the present invention also further broadly include methods for increasing the survival of biological samples, especially during drying and following drying, storing and rehydrating.

[0073] Biological samples for various embodiments of the present invention comprise any suitable biological sample, such as blood platelets and cells. The cells may be any type of cell including, not by way of limitation, erythrocytic cells, eukaryotic cells or any other cell, whether nucleated or non-nucleated.

[0074] The term "erythrocytic cell" is used to mean any red blood cell. Mammalian, particularly human, erythrocytes are preferred. Suitable mammalian species for providing erythrocytic cells include by way of example only, not only human, but also equine, canine, feline, or endangered species.

[0075] The term "eukaryotic cell" is used to mean any nucleated cell, i.e., a cell that possesses a nucleus surrounded by a nuclear membrane, as well as any cell that is derived by terminal differentiation from a nucleated cell, even though the derived cell is not nucleated. Examples of the latter are terminally differentiated human red blood cells. Mammalian, and particularly human, eukaryotes are preferred. Suitable mammalian species include by way of example only, not only human, but also equine, canine, feline, or endangered species.

[0076] The source of the eukaryotic cells may be any suitable source such that the eukaryotic cells may be cultivated in accordance with well known procedures, such as incubating the eukaryotic cells with a suitable serum (e.g., fetal bovine serum). After the eukaryotic cells are cultured, they are subsequently harvested by any conventional procedure, such as by trypsinization, in order to be loaded with a protective preservative. The eukaryotic cells are preferably loaded by growing the eukaryotic cells in a liquid tissue culture medium. The preservative (e.g., an oligosaccharide, such as trehalose) is preferably dissolved in the liquid tissue culture medium, which includes any liquid solution capable of preserving living cells and tissue. Many types of mammalian tissue culture media are known in the literature and available from commercial suppliers, such as Sigma Chemical Company, St. Louis, Mo., USA; Aldrich Chemical Company, Inc., Milwaukee, Wis., USA; and Gibco BRL Life Technologies, Inc., Grand Island, N.Y., USA. Examples of media that are commercially available are Basal Medium Eagle, CRCM-30 Medium, CMRL Medium-1066, Dulbecco's Modified Eagle's Medium, Fischer's Medium, Glasgow Minimum Essential Medium, Ham's F-10 Medium, Ham's F-12 Medium, High Cell Density Medium, Iscove's Modified Dulbecco's Medium, Leibovitz's L-15 Medium, McCoy's 5A Medium (modified), Medium 199, Minimum Essential Medium Eagle, Alpha Minimum Essential Medium, Earle's Minimum Essential Medium, Medium NCTC 109, Medium NCTC 135, RPMMI-1640 Medium, William's Medium E, Waymouth's MB 752/1 Medium, and Waymouth's MB 705/1 Medium.

[0077] Broadly, the preparation of solute-loaded biological sample(s) (e.g., platelets and cells) in accordance with embodiments of the invention comprises the steps of loading one or more biological samples with a solute by placing the biological samples in a solute solution for transferring by fluid phase endocytosis the solute from the solution into the biological sample(s). For increasing the transfer or uptake of the solute from the solute solution, the solute solution temperature, or incubation temperature, may have a temperature above about 25° C., more preferably above 30° C., such as from about 30° C. to about 40° C.

[0078] The method may additionally comprise preventing a decrease in a loading gradient and/or a loading efficiency gradient in the loading of the solute into the biological sample(s). Preventing a decrease in a loading efficiency gradient in the loading of the solute into the biological sample(s) comprises maintaining a positive gradient of loading efficiency (e.g., in %) to concentration (e.g., in mM) of the solute in the solute solution. Preventing a decrease in a loading gradient in the loading of the solute into the biological sample(s) comprises maintaining a concentration of the solute in the solute solution below a certain concentration (e.g., below a concentration ranging from about 35 mM to about 65 mM, more particularly below from about 40 mM to about 60 mM, or below from about 45 mM to about 55 mM, such as below about 50 mM); and/or maintaining a positive gradient of concentration of solute loaded into the biological sample(s) to concentration of the solute in the solute solution.

[0079] The solute solution may be any suitable physiologically acceptable solution in an amount and under conditions effective to cause uptake or "introduction" of the solute from the solute solution into the biological sample(s) for fluid phase endocytosis. A physiologically acceptable solution is a suitable solute-loading buffer, such as any of the buffers stated in the previously mentioned related patent applications, all having been incorporated herein by reference thereto.

[0080] The solute is preferably a carbohydrate (e.g., an oligosaccharide) selected from the following groups of carbohydrates: a monosaccharide, an oligosaccharide (e.g., bioses, trioses, tetroses, pentoses, hexoses, heptoses, etc), a disaccharide (e.g., lactose, maltose, sucrose, melibiose, trehalose, etc), a trisaccharide (e.g., raffinose, melezitose, etc), or tetrasaccharides (e.g., lupeose, stachyose, etc), and a polysaccharide (e.g., dextrans, starch groups, cellulose groups, etc). More preferably, the carbohydrate is a disaccharide, with trehalose being the preferred, particularly since it has been discovered that trehalose does not degrade or reduce in complexity upon being loaded. Thus, in the practice of various embodiments of the invention, trehalose is transferred from a solution into the biological sample without degradation of the trehalose.

[0081] Compositions and embodiments of the invention include platelets that have been manipulated (e.g. by freeze-drying) or modified (e.g. loaded with drugs), and that are useful for therapeutic applications, particularly for platelet transfusion therapy, as surgical or hemostasis aids, such as wound dressings, bandages, and as sutures, and as drug-delivery vehicles. As has been known, human platelets have a phase transition between 12° C. and 20° C. We have found that platelets have a second phase transition between 30° C.

and 37° C. Our discovery of this second phase transition temperature range suggests the possible use of platelets as vehicles for drug delivery because we can load platelets with various useful therapeutic agents without causing abnormalities that interfere with normal platelet responses due to changes, such as in the platelet outer membranes.

[0082] For example, platelets may be loaded with anti-thrombic drugs, such as tissue plasminogen activator (TPA) so that the platelets will collect at the site of a thrombus, as in an heart attack, and release the "clot busting" drug or drugs that are encapsulated and have been targeted by the platelets. Antibiotics can also be encapsulated by the platelets, since lipopolysaccharides produced by bacteria attract platelets. Antibiotic loaded platelets will bring the selected antibiotics to the site of inflammation. Other drugs that can be loaded include anti mitotic agents and anti-angiogenic agents. Since platelets circulate in newly formed vessels associated with tumors, they could deliver anti-mitotic drugs in a localized fashion, and likely platelets circulating in the neovasculature of tumors can deposit anti-angiogenic drugs so as to block the blood supply to tumors. Thus, platelets loaded with a selected drug in accordance with this invention can be prepared and used for therapeutic applications. The drug-loaded platelets are particularly contemplated for blood-borne drug delivery, such as where the selected drug is targeted to a site of platelet-mediated forming thrombi or vascular injury. The so-loaded platelets have a normal response to at least one agonist, particularly to thrombin. Such platelets can be loaded additionally with trehalose, if preservation by freeze-drying is intended.

[0083] The key component for compositions and apparatus of embodiments of the invention, when preservation will be by freeze-drying, is a lyoprotectant, preferably an oligosaccharide, more preferably trehalose, because we have found that platelets that are effectively loaded with trehalose preserve biological properties during freeze-drying (and rehydration). This preservation of biological properties, such as the normal clotting response in combination with thrombin, is necessary so that the platelets following preservation can be successfully used in a variety of therapeutic applications.

[0084] Normal hemostasis is a sequence of interactions in which blood platelets contribute, beginning with adhesion of platelets to an injured vessel wall. The platelets form an aggregate that accelerates coagulation. A complex, termed the glycoprotein (GP) Ib-IX-V complex, is involved in platelet activation by providing a binding site on the platelet surface for the potent agonist, α -thrombin. α -thrombin is a serine protease that is released from damaged tissue. Thus, it is important that the manipulations and modifications in accordance with this invention do not activate the platelets. Further, it is normally preferred that the platelets be in a resting state. Otherwise, the platelets will activate.

[0085] Although for most contemplated therapeutic applications the clotting response to thrombin is key, the inventive freeze-dried platelets after rehydration will also respond to other agonists besides thrombin. These include collagen, ristocetin, and ADP (adenosine diphosphate), all of which are normal platelet agonists. These other agonists typically pertain to specific receptors on the platelet's surface.

[0086] Broadly, the preparation of preserved platelets in accordance with the invention comprises the steps of pro-

viding a source of platelets, loading the platelets with a protective oligosaccharide at a temperature above about 25° C. and less than about 40° C., cooling the loaded platelets to below -32° C., and lyophilizing the platelets.

[0087] In order to provide a source of platelets suitable for the inventive preservation process, the platelets are preferably isolated from whole blood. Thus, platelets used in this invention preferably have had other blood components (erythrocytes and leukocytes) removed prior to freeze-drying. The removal of other blood components may be by procedures well known to the art, which typically involve a centrifugation step.

[0088] The amount of the preferred trehalose loaded inside the inventive platelets is from about 10 mM to about 50 mM, and is achieved by incubating the platelets to preserve biological properties during freeze-drying with a trehalose solution that has up to about 50 mM trehalose therein. Higher concentrations of trehalose during incubation are not preferred, as will be more fully explained later. The effective loading of trehalose is also accomplished by means of using an elevated temperature of from greater than about 25° C. to less than about 40° C., more preferably from about 30° C. to less than about 40° C., most preferably about 37° C. This is due to the discovery of the second phase transition for platelets. As can be seen by FIG. 1, the trehalose loading efficiency begins a steep slope increase at incubation temperatures above about 25° C. up to about 40° C. The trehalose concentration in the exterior solution (that is, the loading buffer) and the temperature during incubation together lead to a trehalose uptake occurring primarily through fluid phase endocytosis. FIG. 2 illustrates the trehalose loading efficiency as a function of incubation time.

[0089] As indicated in patent application Ser. No. 10/052,162, which claims the benefit of patent application Ser. No. 09/501,773, filed Feb. 10, 2000, with respect to common subject matter, the amount of the preferred trehalose loaded inside the cells ranges from about 10 mM to about 50 mM, and is achieved by incubating the cells to preserve biological properties during freeze-drying with a trehalose solution, preferably a trehalose solution that has up to about 50 mM trehalose therein. Higher concentrations of trehalose during incubation are not preferred, particularly since an embodiment of the invention includes preventing a decrease in a loading gradient, or a loading efficiency gradient, in the loading of the solute into the cell. It has been discovered that preventing a decrease in a loading gradient, or a loading efficiency gradient, in the loading of an oligosaccharide (i.e., trehalose) into a cell comprises maintaining a concentration of the oligosaccharide in the oligosaccharide solution below a certain concentration (e.g., below a concentration ranging from about 35 mM to about 65 mM, more particularly below from about 40 mM to about 60 mM, or below from about 45 mM to about 55 mM, such as below about 50 mM). It has been further discovered that preventing a decrease in a loading gradient, or a loading efficiency gradient, in the loading of an oligosaccharide (i.e., trehalose) into a cell comprises maintaining a positive gradient of loading efficiency to concentration of the oligosaccharide in the oligosaccharide solution.

[0090] As further indicated in co-pending patent application Ser. No. 10/052,162, the effective loading of trehalose is also accomplished by means of using an elevated tem-

perature of from greater than about 25° C. to less than about 40° C., more preferably from about 30° C. to less than about 40° C., most preferably about 37° C. This is due to the discovery of the second phase transition for cells.

[0091] Referring now to FIG. 1, there is seen a graphical illustration from co-pending patent application Ser. No. 10/052,162 of the loading efficiency of trehalose plotted versus incubation temperature of human platelets. The trehalose loading efficiency begins a steep slope increase at incubation temperatures above about 25° C. and continues up to about 40° C. The trehalose concentration in the exterior solution (that is, the solute solution or loading buffer) and the temperature during incubation together lead to a trehalose uptake that occurs through fluid phase endocytosis. Example 1 below provides the more specific testing conditions and parameters which produced the graphical illustrations of FIG. 1. It is believed that the graphical illustration of the loading efficiency in FIG. 1 would be generally applicable for cells in general.

[0092] Referring now to FIG. 2, there is seen an illustration from co-pending patent application Ser. No. 10/052,162 of trehalose loading efficiency for human blood platelets as a function of incubation time. More specifically, FIG. 2 graphically illustrates the loading efficiency (cytosolic concentration divided by the extracellular concentration, the sum multiplied by 100) following incubation as a function of incubation time. Example 1 below provides the more specific testing conditions and parameters which produced the graphical illustrations of FIG. 2. It is believed that the graphical illustration of the loading efficiency in FIG. 2 would also be generally applicable for cells in general.

[0093] Referring now to FIG. 3, there is seen a graphical illustration from patent application Ser. No. 10/052,162 of the internal trehalose concentration of human platelets versus external trehalose concentration as a function of 4° C. and 37° C. temperatures at a constant incubation or loading time. In FIG. 4 there is seen a graphical illustration from patent application Ser. No. 10/052,162 of the loading efficiency of trehalose into human platelets as a function of external trehalose concentration. Example 1 below provides the more specific testing conditions and parameters which produced the graphical illustrations of FIGS. 3 and 4. In additional embodiments of the present invention, it is further believed that the general findings illustrated in FIGS. 3 and 4 with respect to platelets are generally broadly applicable to cells in general.

[0094] Thus, applying the findings illustrated in FIG. 3 and in FIG. 4 to solutes and cells in general, a decrease in a loading gradient or a loading efficiency gradient in the loading of a solute into a cell may be prevented. For an embodiment of the present invention and as broadly illustrated in FIG. 3, preventing a decrease in a loading gradient or a loading efficiency gradient in the loading of the solute (e.g., an oligosaccharide such as trehalose) into the cell comprises maintaining a concentration of the solute (e.g., an oligosaccharide such as trehalose) in the solute solution (e.g. an oligosaccharide solution such as a trehalose solution) below a solute concentration ranging from about 35 mM to about 65 mM, more specifically a solute concentration ranging from about 40 mM to about 60 mM, more specifically further a solute concentration ranging from about 45 mM to about 55 mM (e.g., about 50 mM). In another

embodiment of the present invention and as best illustrated in FIG. 4, preventing a decrease in a loading gradient or a loading efficiency gradient in the loading of the solute (e.g., an oligosaccharide, such as trehalose) into the cell comprises maintaining a positive gradient of loading efficiency (e.g., loading efficiency in %) to concentration (e.g., concentration in mM) of the solute in the solute solution (e.g. an oligosaccharide solution, such as a trehalose solution).

[0095] Loading of the solute from the solute solution broadly includes producing and/or forming at least a portion of the biological membrane to entrap and include a solute; and fusing, commingling, or otherwise combining in any suitable manner, the produced and/or formed solute-containing portion of the biological membrane with a lysosome to produce fused matter from which the solute is transferred into the cytoplasm of the biological membrane (e.g., a cell). Producing and/or forming at least a portion of the biological membrane to include the solute comprises transferring or passing the solute from the solute solution against and/or into a portion of the biological membrane for producing and/or forming a vesicle (i.e., an endosomal, phagocytic vesicle) containing the solute. The vesicle subsequently breaks or severs (i.e., "buds off") from the biological membrane into the cytoplasm of the biological sample(s) to fuse with lysosome(s).

[0096] The fusing or combining of the vesicle with a lysosome is caused by recognition sites on both membranes that promote fusion or the combining. The produced fused matter subsequently breaks down or degrades, with the lysosomal membranes being recycled and reloaded in the Golgi. Most sugars are degraded in the lysosome to monosaccharides, which are then transferred to the cytoplasm for further degradation. It is suggested that the mechanism of transfer includes the magnitude of the internal pH in the lysosomes which leads to leakage across the bilayers. The internal, engulfed material within the fused matter contains a reduced pH (e.g., a pH ranging from about 3.5 to about 6.0). In addition there is the presence of acidic hydrolases in the lysosomes.

[0097] The reduced pH, an acidic pH, causes the membrane of the produced fused matter to have an increased permeability. Stated alternatively, lowering the pH of the internal, engulfed material through the fusing of lysosome and vesicles produces an acidic engulfed material within the fused matter, which concomitantly raises or increases the permeability of the membrane of the fused matter. With an increase in permeability, the solute (or any low molecular weight molecules) leaks or passes through the membrane of the fused matter and into the cytoplasm.

[0098] When the solute is a sugar, most sugars hydrolyze within the fused matter. An exception is trehalose, which escapes degradation due to the stability of its associated glycosidic linkage. The broken down components of the lysosome and the vesicles are released into the cytoplasm for further metabolism. The components of sucrose would include glycose and fructose, which are degraded by the well known glycolytic pathway and the TCA cycle to CO₂ and H₂O. Because trehalose remains in tact for effecting the transferring and the loading of the solute into the cytoplasm of the biological sample(s), and does not degrade in conditions found in the lysosome-endosome, trehalose is a preferred solute. However, it is to be understood that while trehalose

is a preferred solute, the spirit and scope of the present invention includes any solute comprising one or more molecules that survive the environmental conditions within the fused matter. More specifically, the solute for various embodiments of the present invention comprises one or more of any molecule(s) that does not degrade under the transferring or loading conditions, or within the environmental conditions within the fused matter resulting from the fusing of lysosome and the vesicle. After the solute is transferred out of the fused matter and into the cytoplasm, stability is conferred on the biological sample for further treatment or processing, such as drying.

[0099] Referring now to FIGS. 10-16 for more specifically describing an embodiment of a mechanism for loading by fluid phase endocytosis a solute from a solute solution into a biological sample (e.g., platelet(s), cell(s), etc.), there is seen in FIG. 10 a biological sample 100 which is exemplarily represented as an intact cell 102 having a plasma membrane 104 internally coated with a protein (e.g., clathrin) 105. The plasma membrane 104 encapsulates cytoplasm 108 having lysosomes 112. The plasma membrane 104 may also encapsulate a nucleus 116 contained within the cytoplasm 108.

[0100] The biological sample 100 is disposed in a solute solution 126 having a solute T (e.g., trehalose). As shown in FIG. 11, the solute T is transferred or passed in direction of the arrow A from the solute solution 126 against and/or into a portion of the membrane 104. As previously indicated, the solute solution 126 may be heated to an elevated temperature (e.g., a temperature from about 30° C. to about 40° C.) to assist in transferring the solute T out of the solute solution 126 and against and/or into a portion of the membrane 104, causing the plasma membrane 104 including its associated protein coat 105 to bulge and/or concave inwardly (as best shown in FIG. 12) to begin the formation of a portion of the membrane 104 having the solute T; that is, a vesicle 120 (see FIG. 13) begins to form. Referring now to FIG. 14 these is seen a partial plan view of the biological sample 100 after the subsequent release or "budding off" of the vesicle 120 into the cytoplasm 108. The vesicle 120 is coated with the protein 105 and contains the solute T. As exemplarily shown in FIG. 15, the vesicle 120 fuses with lysosome 112 to produce and/or form fused matter 124 which is also coated with the protein 105.

[0101] The internal, engulfed material within the fused matter 124 contains a reduced pH (e.g., a pH ranging from about 3.5 to about 6.0) due to ion pumps in the membrane. The acid hydrolases are activated by the low pH. The reduced pH of the internal, engulfed material causes the outer skin or membrane of the produced fused matter 124 to have an increased permeability which facilitates the leakage or passage of the solute (or any low molecular weight molecules) through the outer skin or membrane of the fused matter 124, as illustrated in FIG. 16. As previously indicated, when the solute is trehalose or any other low molecular weight molecule that is immune to the acidic engulfed material within the fused matter 124, trehalose escapes degradation due to the stability of its associated glycosidic linkage and freely passes in tact through the increased-permeability membrane of the fused matter. As previously suggested, the remaining broken down components of the lysosome and the vesicle are released into the cytoplasm for further metabolism. Thus, the solute T is transferred out of

the fused matter **124**, as represented by arrow B in **FIG. 16**, when the permeability of the membrane of the fused matter **124** is increased, and when the engulfed material within the fused matter **124** breaks down or degrades for further metabolism within the cytoplasm. As previously indicated, the solute T preferably remains intact during the loading and/or solute transferring process and within the internal environment of the fused matter **124**. Thus, the solute T remains essentially intact and whole when transferred out of the fused matter **124** and into the cytoplasm **108**. The solute T survives conditions found in the lysosome-endosome and the intact solute T leaks through the outer membrane of the fused matter **124** and into the cytoplasm. The biological sample **100** is now ready for further processing, such as drying, freezing, and subsequent rehydration, etc.

[**0102**] A preferred solute for embodiments of the present invention comprises trehalose. Most sugars degrade in fused lysosome-endosome due to the reduced pH and presence of acid hydrolases. Trehalose is the only non-reducing disaccharide of glucose. **FIG. 17** is an enlarged chemical structural, chain formula diagram of trehalose, a non-reducing disaccharide of glucose, with an arrow pointing to a glycosidic bond. Severing of the glycosidic bond produces glucose which is ineffective in stabilizing dry biological materials. Sucrose, on the other hand, is a non-reducing disaccharide of glucose and fructose. **FIG. 18** is an enlarged chemical structural, chain formula diagram of sucrose, a non-reducing disaccharide of glucose and fructose, with an arrow pointing to a glycosidic bond which is much more susceptible to hydrolysis than the glycosidic bond in trehalose. Trehalose survives conditions found in the lysosome-endosome and intact trehalose leaks into the cytosol of living cells.

[**0103**] Referring now to **FIG. 19**, there is seen a graph of pH vs. % intact (i.e., % non-degraded) for trehalose and sucrose. Trehalose survives survival (i.e., remains 100% intact) down to a pH 1, while sucrose hydrolyzes into glucose and fructose at pH as 5. The % of intact sucrose commences to decrease below a pH of about 6. Thus, sucrose begins to break down at a pH below 6. Example 7 below provides the more specific testing conditions and parameters which produced the graphical, illustrations of **FIG. 19**.

[**0104**] **FIG. 20** is a graph of % leakage of a fluorescent dye, carboxyfluorescein (CF), from phospholipid vesicles as a function of pH and time. As the pH decreases from about 7.0 to a pH of about 3.0 and as time increases (e.g., increases from about 0 to about 20 minutes, the % leakage of the fluorescent dye increases. There is little or no leakage at a pH of about 7.0 or above, but leakage proceeds rapidly at a pH below about 5.0. At pH of about 3.0, 100% of the solute leaked out in 20 minutes. Thus, the leakage of the fluorescent dye CF from liposomes increases with pH and time.

[**0105**] With respect to rate of leakage and the time for leakage, the rate of leakage increases as the pH decreases, as best illustrated in **FIG. 21**, and the time to achieve 100% leak increases with increase in pH, as best shown in **FIG. 22**. **FIG. 21** is a graph of rates of leakage (% leakage/10 minutes) as a function of pH. At pH of 3-4 leakage goes to completion in 20-30 minutes, while at pH 7, three months would be required to complete the leakage. **FIG. 22** is a graph of projected time to achieve 100% leakage, based on

FIGS. 20 and 21, as a function of pH. The time to achieve 100% depletion especially increases after a pH of 5. Example 8 below provides the more specific testing conditions and parameters which produced the graphical, illustrations of **FIGS. 20-22**.

[**0106**] Referring now to **FIGS. 23-26**, there is seen a distribution of Lucifer yellow in intact cells as a function of incubation time. More specifically, **FIG. 23** is a picture of control cells at zero (0) incubation time, showing no leakage of Lucifer yellow dye into the cytoplasm of the control cell. **FIG. 24** is a picture of cells after 1 hour incubation time, showing Lucifer yellow dye in punctate structures (i.e., endocytotic vesicles) with some leakage of Lucifer yellow dye into the cytoplasm. **FIG. 25** is a picture of cells after 3.5 hours incubation time, showing Lucifer yellow dye in punctate structures (i.e., endocytotic vesicles) with more leakage of Lucifer yellow dye into the cytoplasm than the leakage represented in the picture of **FIG. 24**; and **FIG. 26** is a picture of cells after 5.0 hours incubation time, showing a uniform stain of Lucifer yellow dye which suggests that Lucifer yellow dye has leaked into the cytoplasm. Example 9 below provides the more specific testing conditions and parameters which produced the graphical, illustrations of **FIGS. 23-26**. At short incubation times (e.g., incubation times of 1 hour and 3.5 hours), the dye is in punctate structures. With long incubation time (e.g., 5 hours) the staining becomes uniform, suggesting that the dye has leaked into the cytoplasm. Example 9 below provides the more specific testing conditions and parameters which produced the graphical, illustrations of **FIGS. 23-26**.

[**0107**] As may be gathered from various aspects of the figures, in preparing particularly preferred embodiments, platelets may be loaded with trehalose by incubation at 37° C. for about four hours. The trehalose concentration in the loading buffer is preferably 35 mM, which results in an intracellular trehalose concentration of around 20 mM, but in any event is most preferably not greater than about 50 mM trehalose. At trehalose concentrations below about 50 mM, platelets have a normal morphological appearance.

[**0108**] Human platelets have a phase transition between 12° C. and 20° C. We found relatively poor loading when the platelets were chilled through the phase transition. Thus, in practicing the method described by U.S. Pat. No. 5,827,741, of which some of us are coinventors, only a relatively modest amount of trehalose may be loaded into platelets.

[**0109**] In this application, we have further investigated the phase transition in platelets and have found a second phase transition between 30° C. and 37° C. We believe that the excellent loading we obtain at about 37° C. is in some way related to this second phase transition. It may be that other oligosaccharides (other than trehalose) when loaded in this second phase transition in amounts analogous to trehalose could have similar effects.

[**0110**] In any case, it is fortuitous that the loading can be done at elevated temperatures in view of the fact that chilling platelets slowly—a requirement for using the first, or lower, phase transition between 20° C. and 12° C. to introduce trehalose—is well known to activate them (Tablin et al., *J. Cell. Physiol.*, 168, 305313, 1996). Our relatively high temperature loading, regardless of the mechanism, is thus unexpectedly advantageous both by providing increased loading as well as surprisingly, obviating the activation problem.

[0111] Turning to FIG. 6, one sees that we have loaded other, larger molecules into the platelets. In FIG. 6 an illustrative large molecule (FITC dextran) was loaded into the platelets. This illustrates that a wide variety of water-soluble, therapeutic agents can be loaded into the platelets by utilizing the second phase transition, as we have shown may be done with trehalose and with FITC dextran, while still maintaining characteristic platelet surface receptors and avoiding platelet activation.

[0112] We have achieved loading efficiencies by practicing the invention with values as high as 61% after four hours incubation. The plateau is not yet reached after four hours. The high loading efficiency of trehalose is a strong indication that the trehalose is homogeneously distributed, and we expect similar results for loading other therapeutic agents. A loading efficiency of 61% in an external concentration of 25 mM corresponds to a cytosolic concentration of 15 mM.

[0113] We have found that the endocytotic uptake route is blocked at sugar concentrations above 0.1 M. Consequently, we prefer not to use sugar concentrations higher than about 50 mM in the loading buffer, because at some point above this value we have found swelling and morphological changes of the platelets. Thus, we have found that platelets become swollen after four hours incubation at 37° C. in 75 mM trehalose. Further, at concentrations higher than 50 mM the internal trehalose concentration begins to decrease. By contrast to embodiments of the present invention, the platelet method taught by Spargo et al., U.S. Pat. No. 5,736,313, loads with carbohydrate in the range beginning at about 100 mM and going up to 1.5 M. As noted, we find a high concentration of loading buffer, at least with trehalose, to lead to swelling and morphological changes.

[0114] The effective loading of platelets with trehalose is preferably conducted by incubating for at least about two hours, preferably for at least about four hours. After this loading, then the platelets are cooled to below their freezing point and lyophilized.

[0115] Before freezing, the platelets should be placed into a resting state. If not in the resting state, platelets would likely activate. In order to place the platelets in a resting state, a variety of suitable agents, such as calcium channel blockers, may be used. For example, solutions of adenine, adenosine or iloprost are suitable for this purpose. Another suitable agent is PGE1 (prostaglandin E1). It is important that the platelets are not swollen and are completely in the resting state prior to drying. The more they are activated, the more they will be damaged during freeze-drying.

[0116] After the platelets have been effectively loaded with trehalose and are in a resting state, then the loading buffer is removed and the platelets are contacted with a drying buffer.

[0117] The drying buffer should include trehalose, preferably in amounts up to about 100 mM. The trehalose in the drying buffer assists in spatially separating the platelet as well as stabilizing the platelet membranes on the exterior. The drying buffer preferably also includes a bulking agent (to further separate the platelets). Albumin may serve as a bulking agent, but other polymers may be used with the same effect. If albumin is used, it is preferably from the same species as the platelets. Suitable other polymers, for example, are water-soluble polymers such as HES (hydroxy ethyl starch) and dextran.

[0118] The trehalose loaded platelets in drying buffer are then cooled to a temperature below about -32° C. A cooling, that is, freezing, rate is preferably between -30° C. and -1° C./min. and more preferably between about -2° C./min to -5° C./min.

[0119] By the practice of embodiments of the present invention, the addition of a protein (e.g., albumin) to a preservative solution (e.g., an oligosaccharide, preferably trehalose, solution) provides for improved and/or optimal survival of preservative (oligosaccharide)-loaded biological samples (e.g., platelets) during the freeze-drying and rehydration process. It is suggested that the protein (e.g., the albumin) serves as a bulking agent, physically separating the biological samples (e.g., platelets or cells) without contributing significantly to the osmotic pressure of the solution. It is further suggested that the protein (e.g., albumin) requirement is species-specific; that is, if bovine albumin is used with human biological samples (e.g., human platelets), for example, the human biological samples (e.g., platelets) are activated by the bovine (i.e., the foreign) protein. Therefore, the protein (e.g., albumin) is preferably obtained from the same species from which the biological samples (e.g., platelets) were obtained.

[0120] Osmotic pressure when referred to herein is understood to mean the pressure produced by or associated with osmosis (i.e., the movement of a solvent through a semi-permeable membrane (as of a living cell) into a solution of higher solute concentration that tends to equalize the concentrations of solute on the two sides of the membrane). Osmotic pressure is typically dependent on molar concentration and absolute temperature, such as the maximum pressure that develops in a solution separated from a solvent by a membrane permeable only to the solvent, or the pressure that must be applied to a solution to just prevent osmosis.

[0121] Protein when referred to herein means any suitable protein e.g., simple or conjugated protein), including any complex, high polymer containing carbon, hydrogen, oxygen, nitrogen, and usually sulfur, and composed of chains of amino acids connected by peptide linkages.

[0122] Albumin when referred to herein means any suitable albumin (e.g., bovine albumin), including any of a group of water-soluble proteins of wide occurrence in such natural products as milk (lactalbumin), blood serum, eggs (ovalbumin).

[0123] Glass transition temperature (T_g) when referred to herein means the temperature at which an amorphous matter or material (such as glass, a polymer, blood platelets, or a preservative-protein (e.g., a trehalose-albumin solution)) changes from a brittle vitreous (glassy) state to a plastic state (i.e., a state where the material is capable of being molded or being deformed continuously in any direction without rupture).

[0124] In another embodiment of the invention, it has been discovered that protein alters the physical properties of a preservative solution. More specifically, it has been discovered that the protein albumin alters the physical properties of the oligosaccharide trehalose solution as broadly illustrated in FIG. 27, which are graphs representing state diagrams (e.g., glass transition temperature vs. water content) for trehalose:water mixtures and for trehalose-albumin(1/1,

wt/wt):water mixtures. A state diagram is a measure of the glass transition temperatures (T_g) for the respective mixtures (i.e., the various preservative:water mixtures and the various preservative-protein:water mixtures). The state diagrams broadly illustrated in **FIG. 27** were obtained by respectively freeze-drying trehalose alone and freeze-drying a 1:1 (wt:wt) trehalose:albumin solution, and then adding back known amounts of water to the respective freeze-dried solutions. The glass transition temperatures for the trehalose:water solution and for the trehalose/albumin:solution were measured by a differential scanning calorimeter with conventional methods.

[0125] Long-term stability of matter is improved in the vitreous (glassy) state. Thus, long-term stability of a biological sample (e.g., blood platelets, cells, or the like), improves in the glassy state, more specifically when loaded with a preservative having an increased or higher glass transition temperature (T_g). Thus, long-term stability for a biological sample (e.g., blood platelets, cells, or the like), is improved when maintained in a glassy state.

[0126] Generally, an elevated T_g is distinctly advantageous for long term stability. As illustrated in **FIG. 27**, it has been discovered that albumin elevates significantly the T_g of trehalose at the water contents indicated in **FIG. 27**. Only at the very lowest water contents was the T_g not elevated significantly.

[0127] In an embodiment of the present invention, biological sample(s) (e.g., blood platelets, any cells, or the like, all hereinafter referred to as "blood platelets" or "biological sample(s)"), are loaded with a preservative solution to produce preservative-loaded biological sample(s). The preservative solution includes a preservative, protein, and water. The preservative may be any suitable preservative, preferably a preservative comprising an oligosaccharide, such as trehalose. The protein may be any suitable protein, preferably a protein comprising albumin (e.g., bovine albumin). The preservative solution comprises the preservative and protein in any suitable mixing or combination ratio, such as from about 0.20 to about 2.00 parts by weight of the preservative to about 1.00 part by weight of the protein (e.g., from about 0.25 grams to about 1.75 grams of preservative per each gram of protein), preferably from about 0.50 to about 1.50 parts by weight of the preservative to about 1.00 part by weight of the protein, more preferably from about 0.75 to about 1.25 parts by weight of the preservative to about 1.00 part by weight of the protein, and most preferably from about 0.90 to about 1.10 parts by weight of the preservative to about 1.00 part by weight of the protein (e.g., a ratio of about 1 part by weight of preservative to about 1 part by weight of protein). Stated alternatively, but not by way of limitation, the preservative solution comprises from about 60 mM to about 240 mM of the preservative and from about 2% by weight to about 8% by weight of the protein, preferably from about 100 mM to about 200 mM of the preservative and from about 3% by weight to about 7% by weight of the protein, more preferably from about 125 mM to about 175 mM of the preservative and from about 4% by weight to about 6% by weight of the protein (e.g., from about 140 mM to about 160 mM of the preservative (or about 150 mM preservative)) and from about 4.5% by weight to about 5.5% by weight (or about 5% by weight) of the protein.

[0128] The preservative solution in the preservative-solution loaded biological sample(s) generally has higher glass transition temperatures than glass transition glass temperatures for a preservative solution having the preservative, water and no protein. The preservative solution has a gradient of the glass transition temperature (degrees C) to a water content (grams of water per gram of dry weight of preservative and protein) ranging from about 50 to about 900 at a water content of less than about 0.40 grams water per gram of dry weight of preservative and protein. Thus, preservative-loaded biological sample(s) has/have a gradient of the glass transition temperature (degrees C) to a water content (grams of water per gram of dry weight of biological sample(s)) ranging from about 50 to about 900 at a water content of less than about 0.40 grams water per gram of dry weight of biological sample(s). Because the glass transition temperature of the preservative solution increases at a water content of less than about 0.40 (more particularly less than about 0.25) grams of water per gram dry weight of preservative and protein as broadly illustrated in **FIG. 27**, the glass transition temperature of the preservative-loaded biological sample(s) increase(s) at a water content of less than about 0.40 (more particularly less than about 0.25) grams of water per gram dry weight of preservative and protein. Stated alternatively, the preservative-loaded biological sample(s) generally has/have higher glass transition temperatures at a water content (weight of water per dry weight of blood platelets) of less than about 0.40 grams of water per gram dry weight of biological sample(s).

[0129] In another embodiment of the invention and as broadly illustrated in **FIG. 27**, the preservative solution in the preservative-loaded biological sample(s) comprises a greater rate of glass transition temperature per water content (weight of water per dry weight of preservative and protein) increase at a water content of less than about 0.25 grams of water per gram dry weight of preservative and protein than at a water content greater than about 0.25 grams of water per gram dry weight of preservative and protein, more specifically at a water content of less than about 0.15 grams of water per gram dry weight of preservative and protein than at a water content of greater than about 0.15 grams of water per gram dry weight of preservative and protein. Thus, any biological sample(s) loaded with the preservative solution would have a greater rate of glass transition temperature per water content (weight of water per dry weight of biological sample(s)) increase at a water content of less than about 0.25 grams of water per gram dry weight of biological sample(s) than at a water content greater than about 0.25 grams of water per gram dry weight of biological sample(s), more specifically at a water content of less than about 0.15 grams of water per gram dry weight of biological sample(s) than at a water content of greater than about 0.15 grams of water per gram dry weight of biological sample(s). Therefore, the preservative-loaded biological sample(s) may comprise a water content ranging from about 0.02 grams of water per gram of dry weight of biological sample(s) to about 0.40 grams of water per gram of dry weight of biological sample(s), more specifically from about 0.15 grams of water per gram of dry weight of biological sample(s) to about 0.40 grams of water per gram of dry weight of biological sample(s).

[0130] In additional embodiments of the invention and as broadly illustrated in **FIG. 27**, the preservative solution has one of the following gradients of the glass transition tem-

perature (degrees C) to the water content (grams of water per gram of dry weight of preservative and protein): (i) a gradient ranging from about 50 to about 900 at a water content of less than about 0.30 grams of water per gram of dry weight of preservative and protein; (ii) a gradient ranging from about 50 to about 900 at a water content ranging from about 0.02 to less than about 0.40 grams water per gram of dry weight of preservative and protein; (iii) a gradient ranging from about 100 to about 800 at a water content ranging from about 0.15 to about 0.30 grams of water per gram of dry weight of preservative and protein; (iv) a gradient from about 100 to about 800 at a water content ranging from about 0.15 to about 0.30 grams of water per gram of dry weight of preservative and protein; (v) a gradient from about 50 to about 150 at a water content ranging from about 0.20 to about 0.30 grams of water per gram of dry weight of preservative and protein; (vi) a gradient from about 75 to about 125 at a water content ranging from about 0.20 to about 0.30 grams of water per gram of dry weight of preservative and protein; (vii) a gradient from about 700 to about 900 at a water content ranging from about 0.15 to about 0.20 grams of water per gram of dry weight of preservative and protein; and (viii) a gradient from about 750 to about 850 at a water content ranging from about 0.15 to about 0.20 grams of water per gram of dry weight of preservative and protein.

[0131] Correspondingly, therefore, the preservative loaded biological sample(s) (e.g., blood platelets) include one of the following gradients of the glass transition temperature (degrees C) to the water content (grams of water per gram of dry weight of biological sample(s)) (i) a gradient ranging from about 50 to about 900 at a water content of less than about 0.30 grams of water per gram of dry weight of biological sample(s); (ii) a gradient ranging from about 50 to about 900 at a water content ranging from about 0.02 to less than about 0.40 grams water per gram of dry weight of biological sample(s); (iii) a gradient ranging from about 100 to about 800 at a water content ranging from about 0.15 to about 0.30 grams of water per gram of dry weight of biological sample(s); (iv) a gradient from about 100 to about 800 at a water content ranging from about 0.15 to about 0.30 grams of water per gram of dry weight of biological sample(s); (v) a gradient from about 50 to about 150 at a water content ranging from about 0.20 to about 0.30 grams of water per gram of dry weight of biological sample(s); (vi) a gradient from about 75 to about 125 at a water content ranging from about 0.20 to about 0.30 grams of water per gram of dry weight of biological sample(s); (vii) a gradient from about 700 to about 900 at a water content ranging from about 0.15 to about 0.20 grams of water per gram of dry weight of biological sample(s); and (viii) a gradient from about 750 to about 850 at a water content ranging from about 0.15 to about 0.20 grams of water per gram of dry weight of biological sample(s).

[0132] Thus, during processing (e.g., freeze-drying processing) a preservative solution with albumin enters the glassy state at higher water contents. Therefore, correspondingly biological sample(s) loaded with a preservative solution having albumin will enter the glassy state at higher water contents. These effects increase the stability in storing biological sample(s). By way of example only and referencing **FIG. 27**, assuming that primary drying is done at a sample temperature of -50°C ., samples with albumin vitrify (in the glassy state) at a water content as high as about 0.4

gram H_2O /gram dry wt. As illustrated in **FIG. 27**, samples with albumin will enter into the glassy state at a water content as high as about 0.4 gram H_2O /gram dry wt, while those with trehalose alone (i.e., not having albumin) will not enter the glassy state until the water content falls below about 0.15 gram H_2O /gram dry wt. A water content ranging from about 0.15 gram H_2O /gram dry wt to about 0.4 gram H_2O /gram dry wt is a preferred water content range when the water of hydration of membranes and proteins is being removed (i.e., when membranes and proteins are being dehydrated). In addition, the rate of water removal decelerates sharply in this range of water contents, so the samples with albumin would fall below T_g earlier or sooner than those without albumin, leading to decreased opportunities for damage.

[0133] The lyophilization step is preferably conducted at a temperature below about -32°C ., for example conducted at about -40°C ., and drying may be continued until about 95 weight percent of water has been removed from the platelets. During the initial stages of lyophilization, the pressure is preferably at about 10×10^{-6} torr. As the samples dry, the temperature can be raised to be warmer than -32°C . Based upon the bulk of the sample, the temperature and the pressure it can be empirically determined what the most efficient temperature values should be in order to maximize the evaporative water loss. Freeze-dried compositions of the invention preferably have less than about 5 weight percent water.

[0134] The freeze-dried platelets may be used by themselves, dissolved in a physiologically acceptable solution, or may be a component of a biologically compatible (biocompatible) structure or matrix, which provides a surface on or by which the freeze-dried platelets are carried. The freeze-dried platelets can be, for example, applied as a coating to or impregnated in a wide variety of known and useful materials suitable as biocompatible structures for therapeutic applications. The earlier mentioned U.S. Pat. No. 5,902,608, for example, discusses a number of materials useful for surgical aid, wound dressings, bandages, sutures, prosthetic devices, and the like. Sutures, for example, can be monofilament or braided, can be biodegradable or nonbiodegradable, and can be made of materials such as nylon, silk, polyester, cotton, catgut, homopolymers, and copolymers of glycolide and lactide, etc. Polymeric materials can also be cast as a thin film, sterilized, and packaged for use as a wound dressing. Bandages may be made of any suitable substrate material, such as woven or nonwoven cotton or other fabric suitable for application to or over a wound, may optionally include a backing material, and may optionally include one or more adhesive regions on the face surface thereof for securing the bandage over the wound.

[0135] The freeze-dried platelets, whether by themselves, as a component of a vial-compatible structure or matrix, and optionally including other dry or freeze-dried components, maybe packaged so as to prevent rehydration until desired. The packaging may be any of the various suitable packagings for therapeutic purposes, such as made from foil, metallized plastic materials, and moisture barrier plastics (e.g. high-density polyethylene or plastic films that have been created with materials such as SiOx), cooling the trehalose loaded platelets to below their freezing point, and lyophilizing the cooled platelets. The trehalose loading includes incubating the platelets at a temperature from

greater than about 25° C. to less than about 40° C. with a trehalose solution having up to about 50 mM trehalose therein. The process of using such a dehydrated composition comprises rehydrating the platelets. The rehydration preferably includes a prehydration step, sufficient to bring the water content of the freeze-dried platelets to between about 20 weight percent and about 50 percent, preferably from about 20 weight percent to about 40 weight percent.

[0136] When reconstitution is desired, prehydration of the freeze-dried platelets in moisture saturated air followed by rehydration is preferred. Use of prehydration yields cells with a much more dense appearance and with no balloon cells being present. Prehydrated, previously lyophilized platelets of the invention resemble fresh platelets. This is illustrated, for example, by FIG. 7. As can be seen, the previously freeze-dried platelets can be restored to a condition that looks like fresh platelets.

[0137] Before the prehydration step, it is desirable to have diluted the platelets in the drying buffer to prevent aggregation during the prehydration and rehydration. At concentrations below about 3×10^8 cells/ml, the ultimate recovery is about 70% with no visible aggregates. Prehydration is preferably conducted in moisture saturated air, most preferably is conducted at about 37° C. for about one hour to about three hours. The preferred prehydration step brings the water content of the freeze-dried platelets to between about 20 weight percent to about 50 weight percent.

[0138] The prehydrated platelets may then be fully rehydrated. Rehydration may be with any aqueous based solutions, depending upon the intended application. In one preferred rehydration, we used plasma, which resulted in about 90% recovery.

[0139] Since it is frequently desirable to dilute the platelets to prevent aggregation when the freeze-dried platelets are once again hydrated, it may then be desired or necessary for particular clinical applications to concentrate the platelets. Concentration can be by any conventional means, such as by centrifugation. In general, a rehydrated platelet composition will preferably have 10^6 to 10^{11} platelets per ml, more preferably 10^8 to 10^{10} platelets per ml.

[0140] By contrast with the previous attempts at freeze drying platelets, we show here that with a very simple loading, freeze-drying and rehydration protocol one obtains platelets that are morphologically intact after rehydration, and have an identical response to thrombin as do fresh platelets. Moreover, the concentration of thrombin to give this response is a physiological concentration—1 U/ml.

[0141] For example, FIG. 8, panel (A), illustrates the clot formation for fresh platelets and in panel (B) for platelets that have been preserved and then rehydrated in accordance with this invention. The cell counts that were determined after three minutes exposure to thrombin were zero for both the fresh platelets and the previously freeze-dried platelets of the invention.

[0142] FIG. 9 graphically illustrates clotting as measured with an aggregometer. With this instrument one can measure the change in transmittance when a clot is formed. The initial platelet concentration was 250×10^6 platelets/ml, and then thrombin (1 U/ml) was added and the clot formation was monitored with the aggregometer. The absorbance fell sharply and the cell count dropped, to below 2×10^6 platelets/

ml after three minutes, which was comparable to the results when the test was run with fresh platelets as a control.

[0143] Thus, for various embodiments of the invention, platelet or cell counts or concentrations range from about 10^6 to about 10^{11} platelets per ml preservative solution. For additional various embodiments of the invention, platelets may be successfully freeze-dried at concentrations greater than about 10^8 platelets per ml preservative, such as from about 10^8 platelets per ml preservative to about 10^{10} platelets per ml, more specifically such as from about 0.5×10^9 platelets per ml preservative solution to about 10.0×10^9 platelets per ml preservative solution including at least about 5×10^9 platelets per ml preservative solution.

[0144] It has been discovered that at least about 75% of the freeze-dried platelets survive freeze-drying, or may be recovered through hydration. More specifically, at least about 85%, including at least about 90%, of the freeze-dried platelets survive the preservation procedures described herein, and/or may be recovered through hydration. In an embodiment of the invention, the per cent (%) surviving may be a per cent (%) of the number of platelets. It has been further discovered that for any particular concentration of platelets, increasing the quantity of protein and/or the quantity of preservative in the preservative solution, increases the survival or recovery of the freeze-dried platelets at that particular concentration of platelets. By way of example only and referencing now FIG. 41 wherein there is illustrated a graph (recovery (%) vs. cell count (#/ml)) illustrating the effects of increasing trehalose and albumin concentrations on survival of freeze-dried blood platelets, a preservative solution having 1% by weight trehalose and 30 mM albumin limited the platelet or cell survival to around 10^8 cells/ml of preservative solution. However, when the albumin concentration was increased to 5% by weight and the trehalose concentration was increased to 150 mM, cells or platelets illustrated good survival all the way up to about 5×10^9 cells/ml of preservative solution. Preferably the amount of albumin (i.e., the protein) and the amount of preservative (i.e., trehalose) is respectively larger than 1% by weight and 30 mM. Thus, another embodiment of the invention provides for increasing the survival of platelets by increasing the amount of preservative (e.g., trehalose) and/or the amount of protein (e.g., albumin). Preferably, both the amount of preservative and the amount of protein are increased. As indicated and in an embodiment of the invention, but not by way of limitation, the preservative solution comprises, either singularly or in combination, at least about 60 mM preservative and at least about 2% by weight protein e.g., from about 60 mM to about 240 mM of the preservative and from about 2% by weight to about 8% by weight of the protein, preferably at least about 100 mM preservative and at least about 3% by weight protein (e.g., from about 100 mM to about 200 mM of the preservative and from about 3% by weight to about 7% by weight of the protein, more preferably at least about 125 mM preservative and at least about 4% by weight protein (e.g., from about 125 mM to about 175 mM of the preservative and from about 4% by weight to about 6% by weight of the protein [e.g., from about 140 mM to about 160 mM of the preservative (or about 150 mM preservative)) and from about 4.5% by weight to about 5.5% by weight (or about 5% by weight) of the protein].

[0145] Therefore, an embodiment of the present invention broadly provides a process for processing blood platelets comprising suspending blood platelets in a preservative solution (e.g., a preservative solution having water, protein and a preservative) at a concentration greater than about 10^8 platelets per ml. of preservative solution to produce preservative-loaded blood platelets; freeze-drying the preservative-loaded blood platelets; and recovering at least 75% (including at least 85%) of the freeze-dried platelets. As indicated, the preservative solution may comprise from about 60 mM to about 240 mM of a preservative and from about 2% by weight to about 8% by weight protein. The concentration may range from about 0.5×10^9 platelets per ml preservative solution to about 10.0×10^9 platelets per ml preservative solution. The process may additionally comprise storing, prior to recovering, the freeze-dried platelets for more than 600 days (e.g., for about 2 years or longer).

[0146] As indicated for various embodiments of the invention, blood platelets which are freeze-dried with trehalose and albumin respond normally to thrombin at physiological levels. These initial measurements and observations were done by visual observation of clotting and by cell shape change. These observations may be amplified and extended to other agonists, including ristocetin and collagen, through the assistance of aggregometry, which is a technique that measures the time course of platelet clot formation by recording optical density. As the platelets clot and fall out of solution, the optical density decreases. This is a standard clinical assay for platelet clotting.

[0147] Referring now to FIG. 35 there is seen a graph (time vs. transmittance (%)) illustrating aggregometry traces for fresh control and freeze-dried (and rehydrated) platelets. Even though platelet clotting in freeze-dried platelets may not be as effective when compared with the fresh controls (see graph 350 for fresh control platelets vs. graph 354 for rehydrated platelets), it is nevertheless clear from graph 354 in FIG. 35 that the freeze-dried platelets respond to thrombin (e.g., respond at thrombin concentrations at around 1 U/ml), and that the response is within the range of normal controls.

[0148] In another embodiment of the invention, it has been discovered that freeze-dried platelets respond to agonists (e.g., thrombin) below about 1 U/ml. Referring now to FIG. 36, there is seen a graph (thrombin vs. aggregation (%)) illustrating a thrombin dose-response curve 360 for fresh control platelets and a thrombin dose-response curve 364 for rehydrated platelets. From the curve 364 in FIG. 36 it may be seen that the clotting response of rehydrated platelets to thrombin clearly commences at thrombin concentrations below 1 U/ml, with maximal aggregation being achieved at approximately 1 U/ml. As illustrated in FIG. 36, response to thrombin commences at thrombin concentrations ranging from about 0.1 U/ml to about 1.0 U/ml. Between thrombin concentrations ranging from about 0.2 U/ml to about 0.70 U/ml, percent(%) aggregation of the rehydrated platelets ranges from about 20% to about 80%. Between thrombin concentrations ranging from about 0.35 U/ml to about 0.70 U/ml, percent(%) aggregation of the rehydrated platelets ranges from about 40% to about 80%.

[0149] The findings and theories with respect to thrombin may be extended to other agonists, including ristocetin and collagen. Ristocetin is a non-physiological agonist which

requires an active conformation of the GpI-V-IX complex in order to obtain binding and subsequent aggregation. This same complex is required for the binding of von Willebrand factor (vWf) to GPIb complex in vivo, and is used as an in vitro assessment of GPIb availability. Referring now to FIG. 37, there is seen a graph (ristocetin vs. aggregation (%)) illustrating a ristocetin dose-response curve 372 for fresh control platelets and a ristocetin dose-response curve 374 for rehydrated platelets. As illustrated in FIG. 37, response to ristocetin commences at ristocetin concentrations ranging from about 1.0 mg/ml to about 10.0 mg/ml. Between ristocetin concentrations ranging from about 2.0 mg/ml to about 10.0 mg/ml, percent(%) aggregation of the rehydrated platelets ranges from about 10% to about 100%. Between ristocetin concentrations ranging from about 3.5 mg/ml to about 9.0 mg/ml, percent(%) aggregation of the rehydrated platelets ranges from about 40% to about 90%. Between ristocetin concentrations ranging from about 4.0 mg/ml to about 7.0 mg/ml, percent(%) aggregation of the rehydrated platelets ranges from about 60% to about 80%. The foregoing results demonstrate that rehydrated freeze-dried platelets are able to respond to ristocetin in a dose dependent manner, with aggregation for both fresh control and rehydrated freeze-dried platelets reaching about 100%.

[0150] Referring now to FIGS. 38 and 39 there are illustrated respectively collagen dose response curves, generally illustrated as 380, for fresh control platelets, and collagen dose response curves, generally illustrated as 390, for freeze-dried rehydrated platelets. Collagen dose response curves 380 include fresh control platelet curves 382, 384, and 386, respectively representing percent aggregation in response to collagen doses to fresh platelets from three individuals. Collagen dose response curves 390 include rehydrated platelet curves 392, 394, and 398, respectively representing percent aggregation in response to collagen doses to rehydrated platelets from three individuals.

[0151] As illustrated in FIG. 39, rehydrated platelets respond to collagen. In an embodiment of the invention, extracellular calcium (e.g., 0.5 to 4.0 mM, such as 2.0 mM) may be added in the physiological range. As shown in FIG. 38, fresh platelets have a rapid and complete response to about 10 ug/ml collagen, while freeze-dried rehydrated platelets require from about 50 ug/ml to about 100 ug/ml of collagen to initiate an aggregation response. At approximately 200 ug/ml of collagen the response is maximal at about 40% aggregation.

[0152] Although platelets for use in embodiments of this invention preferably have had other blood components removed before freeze-drying, compositions and apparatuses of embodiments of the invention may also include a variety of additional therapeutic agents. For example, particularly for embodiments contemplated in hemostasis applications, antifungal and antibacterial agents are usefully included with the platelets, such as being admixed with the platelets. Embodiments can also include admixtures or compositions including freeze-dried collagen, which provides a thrombogenic surface for the platelets. Other components that can provide a freeze-dried extra-cellular matrix can be used, for example, components composed of proteoglycan. Yet other therapeutic agents that may be included in inventive embodiments are growth factors. When the embodiments include such other components, or admixtures, they are preferably in dry form, and most preferably are also

freeze-dried. We also contemplate therapeutic uses of the composition where additional therapeutic agents may be incorporated into or admixed with the platelets in hydrated form. The platelets, as earlier mentioned, can also be prepared as to encapsulate drugs in drug delivery applications. If trehalose is also loaded into the platelet interiors, then such drug encapsulated platelets may be freeze-dried as has been earlier described.

[0153] The platelets should be selected of the mammalian species for which treatment is intended (e.g. human, equine, canine, feline, or endangered species), most preferably human. The injuries to be treated by applying hemostasis aids with the platelets include abrasions, incisions, burns, and may be wounds occurring during surgery of organs or of skin tissue. The platelets of the invention may be applied or delivered to the location of such injury or wound by any suitable means. For example, application of inventive embodiments to burns can encourage the development of scabs, the formation of chemotactic gradients, of matrices for inducing blood vessel growth, and eventually for skin cells to move across and fill in the burn.

[0154] For transfusion therapy, inventive compositions may be reconstituted (rehydrated) as pharmaceutical formulations and administered to human patients by intravenous injection. Such pharmaceutical formulations may include any aqueous carrier suitable for rehydrating the platelets (e.g., sterile, physiological saline solution, including buffers and other therapeutically active agents that may be included in the reconstituted formulation). For drug delivery, the inventive compositions will typically be administered into the blood stream, such as by i.v.

[0155] Referring in detail now to FIG. 29, there is seen a graph (relative cell count (%) vs. time (days)) illustrating the stability of platelets in the freeze-dried state and suggesting that the shelf life for at least partially active platelets will be at least about two (2) years. Platelets were freeze-dried with trehalose and albumin. The samples were freeze dried in vials, which were then flushed with nitrogen and stored in the dark in an effort at inhibiting photo-oxidation. Upon rehydration and as illustrated in FIG. 29, there was virtually no loss of platelets at storage times approaching 700 days. The response of these platelets to any of the agonists for embodiments of the present invention is normal.

[0156] As previously indicated, freeze-dried platelets may be prehydrated over water vapor in order to increase platelet survival. Referring now to FIG. 30 there is seen a graph (relative percentage vs. volume) illustrating the effects of initial prehydration (followed by rehydration) of platelet volume, and the effects of direct rehydration of platelet volume. More specifically shown in FIG. 30 are fresh control graph 300, prehydrated graph 304, directly rehydrated graph 306. FIG. 30 more particularly shows that prehydrated cells (see prehydrated graph 304) have a cell volume very close to that of fresh controls (see fresh control graph 300) after rehydration was complete. Those directly rehydrated (see fresh control graph 300) are swollen by many fold as indicated on the log scale of volume (fl) axis in FIG. 30.

[0157] Referring now to FIGS. 31 and 32 for illustrating exemplarily how embodiments of the preservative solution effects membrane phase behavior, that membrane lipids in human platelets show a cooperative phase transition

between about 10 and 20° C. FIG. 31 is a graph illustrating the effects of prehydration (over water vapor) on phase behavior of freeze-dried platelets. More specifically shown in FIG. 44 are scattered-point graphs 310 (directly rehydrated platelets scattered points), 312 (prehydrated platelets scattered points), and 314 (fresh control platelets scattered points). As broadly illustrated by scattered-point graph 310 in FIG. 31, direct rehydration alters phase transition significantly (data obtained with Fourier transform infrared spectroscopy). The data represented by scattered-point graphs 310, 312, and 314 show clear differences in the phase transitions, with the prehydrated samples showing phase transitions essentially identical to fresh controls (see scattered-point graph 312 vs. scattered-point graph 314). The directly rehydrated samples are clearly different as shown by scattered-point graph 310.

[0158] FIG. 32 is a graph illustrating the effects of prehydration (over water vapor) on the cooperativity of phase transition. More specifically shown in FIG. 32 are fresh control platelets curve 320 (a reference line for fully hydrated platelets that had never been dehydrated) and rehydrated platelets curve 322. Fresh control platelets curve 320 and rehydrated platelets curve 322 illustrate that prehydration of the platelets over water vapor (see rehydrated platelets curve 322) returned the phase transition parameter to nearly that of fresh control platelets (see fresh control platelets curve 320).

[0159] FIGS. 33 and 34 illustrate exemplarily how embodiments of the preservative solution effects protein secondary structure. Maintenance of protein secondary structure, and therefore function, is preferably required for platelet function after rehydration. Protein secondary structure was probed employing Fourier transform infrared spectroscopy, with the results shown in FIG. 33 as a graph illustrating the effects of prehydration and/or direct rehydration on protein secondary structure in freeze-dried platelets, with direct rehydration altering protein secondary structure relative to controls. More specifically shown in FIG. 33 are directly rehydrated curve 330, prehydrated curve 334, and fresh control platelet curve 332. FIG. 33 illustrates that protein secondary structure is essentially identical in fresh control platelets and in prehydrated platelets that were subsequently rehydrated (see fresh control platelet curve 332 vs. prehydrated curve 334). Platelets that were directly rehydrated, as depicted by directly rehydrated curve 330, show clear changes in the spectrum (i.e., the absorbance(relative units)), indicating damage to the protein secondary structure.

[0160] FIG. 34 is a graph illustrating the effects of prehydration and/or direct rehydration on protein secondary structure in freeze-dried platelets, with prehydration returning protein secondary structure to control levels before direct rehydration in bulk water. More specifically shown in FIG. 34 are directly rehydrated platelet curve 340, and fresh control platelet curve 344. FIG. 34 illustrates the recorded changes in one type of structure (β -sheet) as a function of water content, as was done with respect to the membrane protein structure. As shown by rehydrated platelet curve 340, prehydration returned the protein secondary structure to that seen in fully hydrated platelets, as represented by fresh control platelets curve 344. Thus, protein secondary structure in platelets prehydrated to 0.3 g H₂O/g dry wt returned

to fresh control levels before the platelets which were directly rehydrated in liquid water.

[0161] Embodiments of the present invention will be illustrated by the following set forth examples which are being given by way of illustration only and not by way of any limitation. All parameters such as concentrations, mixing proportions, temperatures, rates, compounds, etc., submitted in these examples are not to be construed to unduly limit the scope of the invention. Abbreviations used in the examples, and elsewhere, are as follows:

- [0162] DMSO=dimethylsulfoxide
- [0163] ADP=adenosine diphosphate
- [0164] PGE1=prostaglandin E1
- [0165] HES=hydroxy ethyl starch
- [0166] FTIR=Fourier transform infrared spectroscopy
- [0167] EGTA=ethylene glycol-bis(2-aminoethyl ether) N,N,N',N', tetra-acetic acid
- [0168] TES=N-tris (hydroxymethyl) methyl-2-aminoethane-sulfonic acid
- [0169] HEPES=N-(2-hydroxyl ethyl) piperazine-N'-(2-ethanesulfonic acid)
- [0170] PBS=phosphate buffered saline
- [0171] HSA=human serum albumin
- [0172] BSA=bovine serum albumin
- [0173] ACD=citric acid, citrate, and dextrose
- [0174] M β CD=methyl- β -cyclodextrin

EXPERIMENTAL

Example 1

[0175] Washing of Platelets. Platelet concentrations were obtained from the Sacramento blood center or from volunteers in our laboratory. Platelet rich plasma was centrifuged for 8 minutes at 320 \times g to remove erythrocytes and leukocytes. The supernatant was pelleted and washed two times (480 \times g for 22 minutes, 480 \times g for 15 minutes) in buffer A (100 mM NaCl, 10 mM KCl, 10 mM EGTA, 10 mM imidazole, pH 6.8). Platelet counts were obtained on a Coulter counter T890 (Coulter, Inc., Miami, Fla.).

[0176] Loading of Lucifer Yellow CH into Platelets. A fluorescent dye, lucifer yellow CH (LYCH), was used as a marker for penetration of the membrane by a solute. Washed platelets in a concentration of 1-2 \times 10⁹ platelets/ml were incubated at various temperatures in the presence of 1-20 mg/ml LYCH. Incubation temperatures and incubation times were chosen as indicated. After incubation the platelets suspensions were spun down for 20 \times at 14,000 RPM (table centrifuge), resuspended in buffer A, spun down for 20 s in buffer A and resuspended. Platelet counts were obtained on a Coulter counter and the samples were pelleted (centrifugation for 45 s 25 at 14,000 RPM, table centrifuge). The pellet was lysed in 0.1% Triton buffer (10 mM TES, 50 mM KCl, pH 6.8). The fluorescence of the lysate was measured on a Perkin-Elmer LSS spectrofluorimeter with excitation at 428 nm (SW 10 nm) and emission at 530 nm (SW 10 nm).

Uptake was calculated for each sample as nanograms of LYCH per cell using a standard curve of LYCH in lysate buffer. Standard curves of LYCH, were found to be linear up to 2000 run ml⁻¹.

[0177] Visualization of cell-associated Lucifer Yellow. LYCH loaded platelets were viewed on a fluorescence microscope (Zeiss) employing a fluorescein filter set for fluorescence microscopy. Platelets were studied either directly after incubation or after fixation with 1% paraformaldehyde in buffer. Fixed cells were settled on poly-L-lysine coated cover slides and mounted in glycerol.

[0178] Loading of Platelets with Trehalose. Washed platelets in a concentration of 1-2 10⁹ platelets/ml were incubated at various temperatures in the presence of 1-20 mg/ml trehalose. Incubation temperatures were chosen from 4° C. to 37° C. Incubation times were varied from 0.5 to 4 hours. After incubation the platelet solutions were washed in buffer A two times (by centrifugation at 14,000 RPM for 20 s in a table centrifuge). Platelet counts were obtained on a coulter counter. Platelets were pelleted (45 S at 14,000 RPM) and sugars were extracted from the pellet using 80% methanol. The samples were heated for 30 minutes at 80° C. The methanol was 10 evaporated with nitrogen, and the samples were kept dry and redissolved in H₂O prior to analysis. The amount of trehalose in the platelets was quantified using the anthrone reaction (Umbreit et al., *Mamometric and Biochemical Techniques*, 5th Edition, 1972). Samples were redissolved in 3 ml H₂O and 6 ml anthrone reagents (2 g anthrone dissolved in 10M sulfuric acid). After vortex mixing, the samples were placed in a boiling water bath for 3 minutes. Then the samples were cooled on ice and the absorbance was measured at 620 nm on a Perkin Elmer spectrophotometer. The amount of platelet associated trehalose was determined using a standard curve of trehalose. Standard curves of trehalose were found to be linear from 6 to 300 μ g trehalose per test tube.

[0179] Quantification of Trehalose and LYCH Concentration. Uptake was calculated for each sample as micrograms of trehalose or LYCH per platelet. The internal trehalose concentration was calculated assuming a platelet radius of 1.2 μ m and by assuming that 50% of the platelet volume is taken up by the cytosol (rest is membranes). The loading efficiency was determined from the cytosolic trehalose or LYCH concentration and the concentration in the loading buffer.

[0180] FIG. 1 shows the effect of temperature on the loading efficiency of trehalose into human platelets after a 4 hour incubation period with 50 mM external trehalose. The effect of the temperature on the trehalose uptake showed a similar trend as the LYCH uptake. The trehalose uptake is relatively low at temperatures of 22° C. and below (below 5%), but at 37° C. the loading efficiency of trehalose is 35% after 4 hours.

[0181] When the time course of trehalose uptake is studied at 37° C., a biphasic curve can be seen (FIG. 2). The trehalose uptake is initially slow (2.8 \times 10⁻¹¹ mol/m²s from 0 to 2 hours), but after 2 hours a rapid linear uptake of 3.3 \times 10⁻¹⁰ mol/m²s can be observed. The loading efficiency increases up to 61% after an incubation period of 4 hours. This high loading efficiency is a strong indication that the trehalose is homogeneously distributed in the platelets rather than located in pinocytosed vesicles.

[0182] The uptake of trehalose as a function of the external trehalose concentration is shown in FIG. 3. The uptake of trehalose is linear in the range from 0 to 30 mM external trehalose. The highest internal trehalose concentration is obtained with 50 mM external trehalose. At higher concentrations than 50 mM the internal trehalose concentration decreases again. Even when the loading buffer at these high trehalose concentrations is corrected for isotonicity by adjusting the salt concentration, the loading efficiency remains low. Platelets become swollen after 4 hours incubation in 75 mM trehalose.

[0183] The stability of the platelets during a 4 hours incubation period was studied using microscopy and flow cytometric analysis. No morphological changes were observed after 4 hours incubation of platelets at 37° C. in the presence of 25 mM external trehalose. Flow cytometric analysis of the platelets showed that the platelet population is very stable during 4 hours incubation. No signs of microvesicle formation could be observed after 4 hours incubation, as can be judged by the stable relative proportion of microvesicle gated cells (less than 3%). The formation of microvesicles is usually considered as the first sign of platelet activation (Owners et al., *Trans. Med. Rev.*, 8, 27-44, 1994). Characteristic antigens of platelet activation include: glycoprotein 53 (gp53, a lysosomal membrane marker), PECAM-1 (platelet endothelial cell adhesion molecule-1, an alpha granule constituent), and P-selection (an alpha granule membrane protein).

Example 2

[0184] Washing Platelets. Platelets were obtained from volunteers in our laboratory. Platelet rich plasma was centrifuged for 8 minutes at 320×g to remove erythrocytes and leukocytes. The supernatant was pelleted and washed two times (480×g for 22 minutes, 480×g for 15 minutes) in buffer A (100 mM NaCl, 10 mM KCl, 10 mM EGTA, 10 mM imidazole, 10 µg/ml PGE1, pH 6.8). Platelet counts were obtained on a Coulter counter T890 (Coulter, Inc., Miami, Fla.).

[0185] Loading Platelets with Trehalose. Platelets were loaded with trehalose as described in Example 1. Washed platelets in a concentration of 1-2×10⁹ platelets/ml were incubated at 37° C. in buffer A with 35 mM trehalose added. Incubation times were typically 4 hours. The samples were gently stirred for 1 minute every hour. After incubation the platelet solutions were pelleted (25 sec in a microfuge) and resuspended in drying buffer (9.5 mM HEPES, 142.5 mM NaCl, 4.8 mM KCl, 1 mM MgCl₂, 30 mM Trehalose, 1% Human Serum Albumin, 10 µg/ml PGE1). In the aggregation studies no PGE1 was added in the drying buffer. Trehalose was obtained from Pfahnstiehl. Human serum albumin was obtained from Sigma.

[0186] Freezing and Drying. Typically 0.5 ml platelet suspensions were transferred in 2 ml Nunc cryogenic vials and frozen in a Cryomed controlled freezing device. Vials were frozen from 22° C. to -40° C. with freezing rates between -30 and -1° C./min and more often between -5 and -2° C./min. The frozen solutions were transferred to a -80° C. freezer and kept there for at least half an hour. Subsequently the frozen platelet suspensions were transferred in vacuum flasks that were attached to a Virtis lyophilizer. Immediately after the flasks were hooked up to the lyophilizer,

they were placed in liquid nitrogen to keep the samples frozen until the vacuum returned to 20×10⁻⁶ Torr, after which the samples were allowed to warm to the sublimation temperature. The condenser temperature was -45° C. Under these conditions, sample temperature during primary drying is about -40° C., as measured with a thermocouple in the sample. It is important to maintain the sample below T_g for the excipient during primary drying (-32° C. for trehalose).

[0187] Rehydration. Vials with originally 0.5 ml platelet suspension were rehydrated in 1 ml PBS buffer/water (1/1). PBS buffer was composed of 9.4 mM Na₂HPO₄, 0.6 mM KH₂PO₄, 100 mM NaCl, pH 7.2). In a few experiments PGE1 was added to the rehydration buffer in a condition of 10 µg/ml or rehydration was performed in plasma/water (1/1).

[0188] Prehydration. Platelet lyophilisates were prehydrated in a closed box with moisture saturated air at 37° C. Prehydration times were between 0 and 3 hours.

[0189] Recovery. The numerical recovery of lyophilized and (prehydrated) platelets was determined by comparing the cell count with a Coulter count T890 (Coulter, Inc., Miami, Fla.) before drying and after rehydration. The morphology of the rehydrated platelets was studied using a light microscope. For this purpose platelets were fixed in 2% paraformaldehyde or glutaraldehyde and allowed to settle on poly-L-lysine coated cover slides for at least 45 minutes. After this the cover slides were mounted and inspected under the microscope. The optical density of freeze-dried and rehydrated platelets was determined by measuring the absorbance of a platelet suspension of 1.0×10⁸ cells/ml at 550 nm on a spectrophotometer.

[0190] Aggregation studies. Dried platelets were rehydrated (after 2 hour prehydration) with 2 aliquots of platelet free plasma (plasma was centrifuged for 5 minutes at 3800×g) diluted with water in 1/1 ratio. Half ml aliquots of this platelet suspension were transferred to aggregation cuvettes with a magnetic stirrer. The response of the platelets to thrombin was tested by adding thrombin (1 U/ml) to the platelet suspension at 37° C. under stirring conditions. After 3 minutes thrombin treated platelet suspensions were inspected for clots and cell counts were done on a Coulter Counter T890.

[0191] Direct rehydration tends toward cell lysis and prehydration leads to aggregation when the cell concentration is 10⁹ cells/ml in the drying buffer. We found also that recovery of prehydrated and rehydrated platelets depends on the cell concentration in the drying buffer. The recovery drops to very low values if the cell concentration is higher than 3×10⁸ cells/ml. At concentrations below 3×10⁸ cells/ml, the recovery is around 70%, and no aggregates were visible. Prehydration resulted in denser cells and the absence of balloon cells.

[0192] Longer prehydration times than 90 minutes did not further improve the cellular density, but slightly activated the platelets. The water content of the pellet increases with increasing prehydration time, and preferably is between about 35% and 50% at the moment of rehydration.

[0193] At higher water contents than 50% water droplets become visible in the lyophilisate (which means that the platelets are in a very hypertonic solution).

[0194] As described by Example 1, platelets were loaded with trehalose by incubation at 37° C. for 4 hours in buffer A with 35 mM trehalose, which yielded platelets with intracellular trehalose concentration of 15-25 mM. After incubation, the platelets were transferred to drying buffer with 30 mM trehalose and 1% HSA as the main excipients.

[0195] The directly rehydrated platelets had a high numerical recovery of 85%, but a considerable fraction (25-50%) of the cells was partly lysed and had the shape of a balloon. Directly rehydrated platelets were overall less dense when compared with fresh platelets.

[0196] The numerical recovery of platelets that were rehydrated in moisture saturated air was only 25% when the platelet concentration was 1×10^9 cells/ml in the drying buffer. This low recovery was due to aggregates that were formed during the prehydration period. But the cells that were not aggregated were more dense than the directly rehydrated platelets and resembled that of fresh platelets.

[0197] Since it appears desirable to dilute the platelets to prevent aggregation during the prehydration step, it may be necessary for clinical applications to concentrate the platelets following rehydration. We therefore also tested the stability of the rehydrated platelets with respect to centrifugation and found that the directly rehydrated platelets had 50% recovery after centrifugation, while the prehydrated ones had 75% recovery following centrifugation. Thus, we conclude that the inventive platelets can be concentrated without ill effect.

Example 3

[0198] We view trehalose as the main lyoprotectant in the drying buffer. However, other components in the drying buffer, such as albumin, can improve the recovery. In the absence of external trehalose in drying buffer, the numerical recovery is only 35%. With 30 mM trehalose in the drying buffer the recovery is around 65%. A combination of 30 mM trehalose and 1% albumin gave a numerical recovery of 85%.

Example 4

[0199] Typically 0.5 ml platelet suspensions were transferred in 2 ml Nunc cryogenic vials and frozen in a Cryomed controlled freezing device. Vials were frozen from 22° C. to -40° C. with freezing rates between -30° C./min and -1° C./min and more often between -5° C. and -2° C./min. The frozen solutions were transferred to a -80° C. freezer and kept there for at least half an hour. Subsequently the frozen platelet suspensions were transferred in vacuum flasks that were attached to a Virtus lyophilizer. Immediately after the flasks were hooked up to the lyophilizer, they were placed in liquid nitrogen to keep the samples frozen until the vacuum returned to 20×10^{-6} Torr, after which the samples were allowed to warm to the sublimation temperature. The condenser temperature was -45° C. Under these conditions, sample temperature during primary drying is about -40° C., as measured with a thermocouple in the sample. It is important to maintain the sample below T_g for the excipient during primary drying (-32° C. for trehalose). Only minor differences in recovery were found as a function of the freezing rate. The optimal freezing rate was found to be between 2° C. and 5° C./minute.

Example 5

[0200] Response of freeze-dried platelets to thrombin (1 U/ml) was compared with that of fresh platelets. The platelet concentration was 0.5×10^8 cells/ml in both samples. 500 μ l platelets solution was transferred into aggregation vials. Thrombin was added to the samples and the samples were stirred for 3 minutes at 37° C. The cell counts that were determined after 3 minutes were 0 for both the fresh and the freeze-dried platelets. The response to thrombin was determined by a cleavage in glycoprotein Ib-(GPIb). This was detected by using monoclonal antibodies and flow cytometry. Thus, the pattern seen after addition of thrombin was a reduced amount of GP Ib on the platelet surface.

[0201] The response of lyophilized, prehydrated, and rehydrated platelets (Examples 1 and 2) to thrombin (1 U/ml) was found to be identical compared with that of fresh platelets. In both fresh and rehydrated platelets a clot was formed within 3 minutes at 37° C. These clots are illustrated by FIG. 8, panels (A) and (B). When cell counts were done with the Coulter counter, we found no cells present, indicating that all platelets participated in forming the clot illustrated in panel (B).

Example 6

[0202] Reactions with other agonists were studied. Platelet suspensions of the inventive platelets were prepared with 50×10^6 platelets/ml. Different agonists were then added and subsequently counted with a Coulter counter to determine the percentage of platelets involved in the visually observable clot formation. The cell count was between 0 and 2×10^6 platelets/ml: after 5 minutes with 20 μ g/ml collagen; after 5 minutes with 20 μ M ADP; after 5 minutes with 1.5 mg/ml ristocetin. This means that the percentage of platelets that are involved in clot formation is between 95-100% for all the agonists tested. The agonist concentrations that were used are all physiological. In all cases the percentage of clotted platelets was the same as fresh control platelets.

Example 7

[0203] Trehalose and sucrose solutions were prepared in water (100 mM). The solutions were heated to 70° C. for 30 minutes, after which the solutions were analyzed by HPLC (high performance liquid chromatograph). Trehalose survived this treatment down to pH 1.0, while most of the sucrose was hydrolyzed to glucose and fructose at pH as high as 5. At lower temperatures this pattern persisted, although the time required to hydrolyze the sucrose increased. It is well established that the pH in lysosomes is 4-5, so it follows that sucrose is likely to be degraded in lysosomes, while trehalose should escape damage. The residence time in the lysosomes would be expected to be critical in this regard. At 370 C, for example, sucrose would experience minimal degradation if the residence time is 10 minutes, but degradation would be extensive if the residence time were on the order of hours.

Example 8

[0204] Membranes become leaky at the pH found in lysosomes. Liposomes composed of the phospholipids POPC (palmitoylcholine) and PS (phosphatidylserine) (9:1) were prepared by extrusion through 100 nm filters. A marker for permeability, the

fluorescent marker carboxyfluorescein (CF) was trapped in liposomes at a concentration of 0.5 M during the extrusion. External CF was removed by passing the liposomes through a Sephadex column. The liposomes were then subjected to decreased pH. CF is fluorescent, but self-quenching at the concentration at which it was trapped in the liposomes. When the trapped CF leaks into the external medium, it becomes diluted, and fluorescence increases. From the rate of increase in fluorescence it is possible to deduce the permeability.

Example 9

[0205] Leakage from lysosomes in vivo is in reasonable agreement with the in vitro data. Cells were incubated in a fluorescent probe, Lucifer yellow. This particular probe was chosen as a tracer since it is approximately the same size as a disaccharide. The cells were washed free of extracellular Lucifer yellow and then observed by fluorescence microscopy. The results are shown in FIGS. 23-26. When the cells were incubated in the dye for 1 to 3.5 hours, punctuate staining was clearly seen, indicating the presence of the dye in endosomes or lysosomes. However, by 5 hours much of the punctuate staining disappeared and the cytoplasm acquired a uniform fluorescence. Thus, 3.5 to 5 h hours are required for appreciable leakage to occur. Thus, there is reasonable agreement between the two measurements.

Example 10

[0206] Trehalose survives passage through lysosomes in vivo, while other sugars do not. Platelet cells were incubated for four hours in 100 mM trehalose, sucrose, or raffinose, respectively. The platelet cells were then homogenized in 60% methanol, from which the large particles were pelleted by centrifugation. The supernatant was removed, and analyzed by HPLC. The results showed that trehalose was recovered intact, with no evidence of degradation. Raffinose appeared to be completely hydrolyzed. Sucrose was partially hydrolyzed, but significant amounts of intact sucrose were obtained, nevertheless. It may well be that the difference between raffinose and sucrose lies in the fact that raffinose is a trisaccharide and thus might be expected to leak across the lysosomal membrane more slowly than does sucrose. Thus, with increased residence time hydrolysis would go further towards completion. Even a small amount of hydrolysis might not be acceptable; the monosaccharides that are produced as a result of the hydrolysis are all reducing sugars, and all show the Maillard reaction with dry proteins, a reaction that denatures the protein irreversibly.

Example 11

[0207] Mouse platelets were prepared essentially as has been previously described for human platelets and loaded with trehalose at 37° C. employing the membrane fluctuations that occur during high phase transition (30-40° C.). In mouse platelets phase transitions tended to be much broader than in human platelets, but loading with trehalose proceeded essentially similar to that seen in human platelets.

[0208] Freeze-drying was conducted in a virtually identical manner to human platelets. Freeze-dried platelets were rehydrated over water vapor with approximately 100% recovery. The rehydrated cells were labeled with the fluorescent dye carboxy-methyl fluorescein diacetate (CMFDA)

and labeled platelets were injected into mouse tail veins. Platelet circulation times were obtained by serial eye-bleeds. Blood was collected into heparinized tubes and samples were fixed in 1% paraformaldehyde. Samples were analyzed on a Becton-Dickinson FACsCalibur flow cytometer. Serial samples were obtained for both control animals (n=8) (fresh platelets) and experimental animals (freeze-dried platelets) (n=5). In FIG. 40 there is seen a percent circulation vs. survival of rehydrated (n=5) and control (n=8) carboxy-methyl fluorescein diacetate (CMFDA) labeled platelets circulating in mice. The half-life of fresh platelets in the circulation was approximately 40 hours, while that for the freeze-dried platelets was approximately 20 hours. Thus, the freeze-dried platelets do not circulate for as long as the fresh controls, however they were not immediately removed from the circulation by the reticuloendothelial system, as might occur with platelets possessing exposed antigens on their surface.

[0209] As part of determinations of antigenicity of the freeze-drying buffer, we examined white blood cells counts from animals injected with freeze-drying buffer. There was no apparent antigenic response to the freeze-drying buffer over a 48 hour period. In addition, blood smears were available from freeze-dried transfused animals, which were analyzed as shown below in Table 1, thus providing data on the antigenicity of the freeze-dried platelets.

TABLE 1

Mouse (injected 0.25 ml of freeze drying buffer)				
	0 Hr	24 Hr	48 Hr	p-value
Neutrophils	16	11	16	0.0895
Eosinophils	9	8	7	0.3135
Lymphocytes	63	73	60	0.5545
Monocytes	12	9	17	0.6538

Example 12

[0210] We sought to determine the response of freeze-dried mouse platelets to various physiological agonists. Below in Table II are listed the response of fresh and freeze-dried platelets to three physiological agonists, thrombin, collagen and ADP. Platelets were examined in the presence and absence of platelet poor plasma (PPP) to determine the specific role of platelet surface proteins and their interaction with agonist.

TABLE II

	Thrombin		Collagen		ADP	
	1 U/ml PPP	1 U/ml No PPP	200 ug/ml PPP	200 ug/ml No PPP	200 uM PPP	200 uM No PPP
Fresh	99	99	94	99	44	17
Freeze-Dried	96	92	40	27	32	11

[0211] It is clear from the foregoing data that the thrombin response was unchanged by freeze-drying. On the other hand, the response to collagen and ADP were attenuated to some extent, but remain nonetheless. Freeze-dried platelet aggregation to collagen and ADP both appeared to require the presence of plasma.

Conclusion

[0212] Embodiments of the present invention provide that trehalose, a sugar found at high concentrations in organisms that normally survive dehydration, can be used to preserve biological structures in the dry state. Human blood platelets can be loaded with trehalose under specified conditions, and the loaded cells can be freeze dried with excellent recovery. Additional embodiments of the present invention provide that trehalose may be used to preserve nucleated (eukaryotic) cells.

[0213] It has been shown that mouse platelets may be successfully freeze-dried, and when rehydrated they respond appropriately to physiological agonists. When the freeze-dried mouse platelets were injected into mice *in vivo*, they circulate with a half-life of 20 hours, approximately 50% of fresh control platelets. Such a circulation time achieved in humans will be appropriate for therapeutic applications, particularly in trauma situations.

[0214] While the present invention has been described herein with reference to particular embodiments thereof, a latitude of modification, various changes and substitutions are intended in the foregoing disclosure, and it will be appreciated that in some instances some features of the invention will be employed without a corresponding use of other features without departing from the scope and spirit of the invention as set forth. Therefore, many modifications may be made to adapt a particular situation or material to the teachings of the invention without departing from the essential scope and spirit of the present invention. It is intended that the invention not be limited to the particular embodiment disclosed as the best mode contemplated for carrying out this invention, but that the invention will include all embodiments and equivalents falling within the scope of the appended claims.

What is claimed is:

1. A method for loading a preservative into a biological sample comprising:

providing a preservative solution having a preservative, water and protein; and

loading a biological sample with the preservative solution to produce a preservative-loaded biological sample wherein said preservative solution generally has higher glass transition temperatures than glass transition temperatures for a preservative solution having the preservative, water and no protein.

2. The method of claim 1 wherein said preservative solution in said preservative-loaded biological sample comprises a gradient of the glass transition temperature (degrees C.) to a water content (grams of water per gram of dry weight of preservative and protein) ranging from about 50 to about 900 at a water content of less than about 0.40 grams of water per gram of dry weight of preservative and protein.

3. The method of claim 1 wherein said glass transition temperature of said preservative solution in said preservative-loaded biological sample increases at a water content of less than about 0.40 grams of water per gram dry weight of preservative and protein.

4. The method of claim 1 wherein said preservative solution in said preservative-loaded biological sample comprises a greater rate of glass transition temperature per water content (weight of water per dry weight of preservative and

protein) increase at a water content of less than about 0.25 grams of water per gram dry weight of preservative and protein than at a water content greater than about 0.25 grams of water per gram dry weight of preservative and protein.

5. The method of claim 1 wherein said preservative solution in said preservative-loaded biological sample comprises a greater rate of glass transition temperature per water content (weight of water per dry weight of preservative and protein) increase at a water content of less than about 0.15 grams of water per gram dry weight of preservative and protein than at a water content of greater than about 0.15 grams of water per gram dry weight of preservative and protein.

6. The method of claim 1 wherein said preservative solution in said produced preservative-loaded biological sample generally has said higher glass transition temperatures at a water content (weight of water per dry weight of preservative and protein) of less than about 0.25 grams of water per gram dry weight of preservative and protein.

7. The method of claim 1 wherein said preservative comprises an oligosaccharide.

8. The method of claim 7 wherein said oligosaccharide comprises trehalose.

9. The method of claim 1 wherein said preservative-loaded biological sample comprise a water content ranging from about 0.02 grams of water per gram of dry weight of preservative and protein to about 0.40 grams of water per gram of dry weight of preservative and protein.

10. The method of claim 1 wherein said preservative-loaded biological sample comprise a water content ranging from about 0.15 grams of water per gram of dry weight of preservative and protein to about 0.40 grams of water per gram of dry weight of preservative and protein.

11. The method of claim 1 wherein said protein comprises albumin.

12. The method of claim 1 wherein said albumin comprises bovine albumin.

13. The method of claim 1 wherein a gradient of the glass transition temperature (degrees C.) to the water content (grams of water per gram of dry weight of preservative and protein) ranges from about 50 to about 900 at a water content of less than about 0.30 grams of water per gram of dry weight of preservative and protein.

14. The method of claim 1 wherein a gradient of the glass transition temperature (degrees C.) to the water content (grams of water per gram of dry weight of preservative and protein) ranges from about 50 to about 900 at a water content ranging from about 0.02 to less than about 0.40 grams of water per gram of dry weight of preservative and protein.

15. The method of claim 1 wherein a gradient of the glass transition temperature (degrees C.) to the water content (grams of water per gram of dry weight of preservative and protein) ranges from about 100 to about 800 at a water content ranging from about 0.15 to about 0.30 grams of water per gram of dry weight of preservative and protein.

16. The method of claim 1 wherein a gradient of the glass transition temperature (degrees C.) to the water content (grams of water per gram of dry weight of preservative and protein) ranges from about 50 to about 150 at a water content ranging from about 0.20 to about 0.30 grams of water per gram of dry weight of preservative and protein.

17. The method of claim 1 wherein a gradient of the glass transition temperature (degrees C.) to the water content (grams of water per gram of dry weight of preservative and

protein) ranges from about 75 to about 125 at a water content ranging from about 0.20 to about 0.30 grams of water per gram of dry weight of preservative and protein.

18. The method of claim 1 wherein a gradient of the glass transition temperature (degrees C.) to the water content (grams of water per gram of dry weight of preservative and protein) ranges from about 700 to about 900 at a water content ranging from about 0.15 to about 0.20 grams of water per gram of dry weight of preservative and protein.

19. The method of claim 1 wherein a gradient of the glass transition temperature (degrees C.) to the water content (grams of water per gram of dry weight of preservative and protein) ranges from about 750 to about 850 at a water content ranging from about 0.15 to about 0.20 grams of water per gram of dry weight of preservative and protein.

20. The method of claim 1 wherein said preservative solution comprises said preservative and said protein in a weight ratio ranging from about 0.25 grams to about 1.75 grams of preservative per each gram of protein.

21. The method of claim 1 wherein said preservative solution comprises said preservative and said protein in an approximate 1:1 weight ratio.

22. The method of claim 1 wherein said preservative-loaded biological sample has said higher glass transition temperatures.

23. The method of claim 9 wherein said preservative-loaded biological sample has said higher glass transition temperatures.

24. A biological sample produced in accordance with the method of claim 1.

25. A biological composition comprising

a biological sample having a preservative solution including a preservative, water, and protein, and generally having higher glass transition temperatures than glass transition temperatures for the biological sample loaded with the preservative, water, but no protein.

26. The biological composition of claim 25 wherein said biological sample comprises a gradient of the glass transition temperature (degrees C.) to a water content (grams of water per gram of dry weight biological sample) ranging from about 50 to about 900 at a water content of less than about 0.40 grams of water per gram of dry weight biological sample.

27. The biological composition of claim 25 wherein a gradient of the glass transition temperature (degrees C.) to the water content (grams of water per gram of dry weight of biological sample) ranges from about 50 to about 150 at a water content ranging from about 0.20 to about 0.30 grams of water per gram of dry weight of biological sample.

28. The biological composition of claim 25 wherein the gradient of the glass transition temperature (degrees C.) to the water content (grams of water per gram of dry weight biological sample) ranges from about 75 to about 125 at a water content ranging from about 0.20 to about 0.30 grams of water per gram of dry weight biological sample.

29. The biological composition of claim 25 wherein a gradient of the glass transition temperature (degrees C.) to the water content (grams of water per gram of dry weight of biological sample) ranges from about 700 to about 900 at a water content ranging from about 0.15 to about 0.20 grams of water per gram of dry weight of biological sample.

30. The biological composition of claim 25 wherein a gradient of the glass transition temperature (degrees C.) to the water content (grams of water per gram of dry weight of

biological sample) ranges from about 750 to about 850 at a water content ranging from about 0.15 to about 0.20 grams of water per gram of dry weight of biological sample.

31. The biological composition of claim 25 wherein said preservative comprises an oligosaccharide.

32. The biological composition of claim 31 wherein said oligosaccharide comprises trehalose.

33. The biological composition of claim 25 wherein said protein comprises albumin.

34. A process for processing biological samples comprising:

providing a preservative solution having a preservative, water, and protein;

suspending biological samples in the preservative solution at a concentration greater than about 10^8 biological samples per ml. of preservative solution to produce preservative-loaded biological samples;

freeze-drying the preservative-loaded biological samples; and

recovering at least 75% of the freeze-dried biological samples.

35. The process of claim 34 wherein said preservative solution comprises from about 60 mM to about 240 mM of said preservative and from about 2% by weight to about 8% by weight of said protein.

36. The process of claim 34 wherein said concentration ranges from about 0.5×10^9 biological samples per ml preservative solution to about 10.0×10^9 biological samples per ml preservative solution.

37. The process of claim 34 wherein said concentration ranges from about 0.5×10^9 biological samples per ml preservative solution to about 10.0×10^9 biological samples per ml preservative solution, and said recovering includes recovering at least 85% by weight of the freeze-dried biological samples.

38. The process of claim 34 additionally comprising storing, prior to recovering, the freeze-dried biological samples for more than 600 days.

39. A process for preserving protein structure in a biological sample comprising:

providing a preservative solution having a preservative, water and protein;

loading a biological sample with the preservative solution to produce a preservative-loaded biological sample;

dehydrating the preservative-loaded biological sample while maintaining a residual water content in the biological sample equal to or less than about 0.30 gram of residual water per gram of dry weight biological sample to preserve protein structure of the biological sample upon rehydrating after storage;

storing the dehydrated preservative-loaded biological sample; and

rehydrating the stored dehydrated preservative-loaded biological sample with water vapor to preserve protein structure of the biological sample.

40. The process of claim 39 wherein said rehydrating the stored dehydrated preservative-loaded biological sample with water vapor comprises increasing the water content of the preservative-loaded biological sample until the preser-

vative-loaded biological sample has a water content equal to or less than about 0.30 grams of water per gram of dry weight biological sample.

41. The process of claim 39 additionally comprising directly hydrating with bulk water the rehydrated preservative-loaded biological sample.

42. A dehydrated composition for mammalian therapy comprising: freeze-dried biological samples comprising a preservative solution for preserving biological properties during freeze-drying and rehydration, wherein said preservative solution includes water, protein, and a preservative, and said biological samples are rehydratable so as to have a normal response to at least one agonist.

43. The dehydrated composition of claim 42 wherein said normal response to at least one agonists includes a response to thrombin in a physiological concentration commencing at thrombin concentrations ranging from about 0.1 U/ml to about 1.0 U/ml, and wherein between thrombin concentrations ranging from about 0.2 U/ml to about 0.70 U/ml, percent(%) aggregation of the rehydrated biological samples ranges from about 20% to about 80%.

44. The dehydrated composition of claim 42 wherein said normal response to at least one agonists includes a response to ristocetin in a physiological concentration commencing at ristocetin concentrations ranging from about 1.0 mg/ml to about 10.0 mg/ml.

45. The dehydrated composition of claim 42 wherein said normal response to at least one agonists includes a response to ristocetin in a physiological concentration and between ristocetin concentrations ranging from about 2.0 mg/ml to about 10.0 mg/ml, percent(%) aggregation of the rehydrated biological samples ranges from about 10% to about 100%.

46. The dehydrated composition of claim 42 wherein said normal response to at least one agonists includes a response to ristocetin in a physiological concentration and between ristocetin concentrations ranging from about 3.5 mg/ml to about 9.0 mg/ml, percent(%) aggregation of the rehydrated biological samples typically ranges from about 40% to about 90%.

47. The dehydrated composition of claim 42 wherein said normal response to at least one agonists includes a response to ristocetin in a physiological concentration and between ristocetin concentrations ranging from about 4.0 mg/ml to about 7.0 mg/ml, percent(%) aggregation of the rehydrated biological samples ranges from about 60% to about 80%.

48. A process for loading a preservative into a biological sample comprising:

providing a preservative solution having a preservative, water and protein;

disposing a biological sample in the preservative solution for loading the preservative from the preservative solution into the biological sample to produce a preservative-loaded biological sample wherein said preservative solution generally has higher glass transition temperatures than glass transition temperatures for a preservative solution having the preservative, water and no protein; and

preventing a decrease in a loading efficiency gradient in the loading of the preservative into the biological sample.

49. The process of claim 48 wherein said preservative comprises an oligosaccharide and said preventing a decrease

in a loading efficiency gradient in the loading of the oligosaccharide into the biological sample comprises maintaining a concentration of the oligosaccharide in the oligosaccharide solution below about 50 mM.

50. The process of claim 48 wherein said loading comprises loading by fluid phase endocytosis.

51. The process of claim 49 wherein said loading comprises loading by fluid phase endocytosis.

52. The process of claim 48 wherein said preservative comprises an oligosaccharide and said preventing a decrease in a loading efficiency gradient in the loading of the oligosaccharide into the biological sample comprises maintaining a positive gradient of loading efficiency to concentration of the oligosaccharide in the oligosaccharide solution.

53. The process of claim 48 wherein said preservative comprises an oligosaccharide and said preventing a decrease in a loading efficiency gradient in the loading of the oligosaccharide into the biological sample comprises maintaining a positive gradient of loading efficiency (%) to concentration (mM) of the oligosaccharide in the oligosaccharide solution.

54. The process of claim 52 wherein said oligosaccharide comprises trehalose.

55. The process of claim 53 wherein said oligosaccharide comprises trehalose.

56. A process for loading a preservative into a biological sample comprising:

providing a preservative solution having a preservative, water and protein;

disposing a biological sample in the preservative solution for loading the preservative from the preservative solution into the biological sample to produce a preservative-loaded biological sample wherein said preservative solution generally has higher glass transition temperatures than glass transition temperatures for a preservative solution having the preservative, water and no protein; and

preventing a decrease in a loading gradient in the loading of the oligosaccharide into the biological sample.

57. The process of claim 56 wherein said preservative comprises an oligosaccharide and said preventing a decrease in a loading gradient in the loading of the oligosaccharide into the biological sample comprises maintaining a concentration of the oligosaccharide in the oligosaccharide solution below about 50 mM.

58. The process of claim 56 wherein said preservative comprises an oligosaccharide and said loading comprises loading by fluid phase endocytosis.

59. The process of claim 57 wherein said loading comprises loading by fluid phase endocytosis.

60. The process of claim 56 wherein said preservative comprises an oligosaccharide and said preventing a decrease in a loading gradient in the loading of the oligosaccharide into the biological sample comprises maintaining a positive gradient of concentration of oligosaccharide loaded into the biological sample to concentration of the oligosaccharide in the oligosaccharide solution.

61. The process of claim 60 wherein said oligosaccharide comprises trehalose.

专利名称(译)	方法和治疗血小板		
公开(公告)号	US20040191903A1	公开(公告)日	2004-09-30
申请号	US10/724545	申请日	2003-11-28
[标]申请(专利权)人(译)	CROWE约翰·H· TABLIN FERN WOLKERS WILLEM WALKER NAOMI LOOPER SHERI TSVETKOVA NELLY中号 TOROK索尔特		
申请(专利权)人(译)	CROWE约翰H. TABLIN FERN WOLKERS WILLEM WALKER NAOMI LOOPER SHERI TSVETKOVA NELLY M. TOROK索尔特		
当前申请(专利权)人(译)	CROWE约翰H. TABLIN FERN WOLKERS WILLEM WALKER NAOMI LOOPER SHERI TSVETKOVA NELLY M. TOROK索尔特		
[标]发明人	CROWE JOHN H TABLIN FERN WOLKERS WILLEM WALKER NAOMI LOOPER SHERI TSVETKOVA NELLY M TOROK ZSOLT		
发明人	CROWE, JOHN H. TABLIN, FERN WOLKERS, WILLEM WALKER, NAOMI LOOPER, SHERI TSVETKOVA, NELLY M. TOROK, ZSOLT		
IPC分类号	A01N1/00 A01N1/02 A61B5/00 C12N5/00 C12N5/02		
CPC分类号	A01N1/00 A01N1/0205 A01N1/02 A01N1/0221		
优先权	60/430040 2002-11-29 US		
外部链接	Espacenet USPTO		
摘要(译)			

一种将防腐剂加载到生物样品中的方法，包括提供具有防腐剂，水和蛋白质的防腐剂溶液，并将生物样品加载到防腐剂溶液中以产生具有防腐剂溶液的防腐剂生物样品，所述生物样品通常包括更高的玻璃化转变温度具有防腐剂，水和无蛋白质的防腐剂溶液的玻璃化转变温度。一种处理生物样品的方法，包括将生物样品悬浮在浓度大于约10⁸个血小板/ml的防腐剂溶液中。制备含有防腐剂的生物样品的防腐剂溶液，冷冻干燥装有防腐剂的生物样品，并回收至少75%的冷冻干燥的生物样品。一种生物样品组合物，其包含装载有具有防腐剂，水和蛋白质的防腐剂溶液的生物样品，并且通常还具有比载有防腐剂，水但不含蛋白质的生物样品的玻璃化转变温度更高的玻璃化转变温度。




FIG. 1




FIG. 2